

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



Perel, P; Roberts, I; Ker, K (2013) Colloids versus crystalloids for fluid resuscitation in critically ill patients. *The Cochrane database of systematic reviews*, 2 (2). CD000567. ISSN 1469-493X DOI: <https://doi.org/10.1002/14651858.CD000567.pub6>

Downloaded from: <http://researchonline.lshtm.ac.uk/638999/>

DOI: [10.1002/14651858.CD000567.pub6](https://doi.org/10.1002/14651858.CD000567.pub6)

#### Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

# Colloids versus crystalloids for fluid resuscitation in critically ill patients (Review)

Perel P, Roberts I, Ker K



**THE COCHRANE  
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2013, Issue 2

<http://www.thecochranelibrary.com>



---

Colloids versus crystalloids for fluid resuscitation in critically ill patients (Review)  
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
BACKGROUND . . . . .	2
OBJECTIVES . . . . .	3
METHODS . . . . .	3
RESULTS . . . . .	4
Figure 1. . . . .	5
DISCUSSION . . . . .	6
AUTHORS' CONCLUSIONS . . . . .	7
ACKNOWLEDGEMENTS . . . . .	7
REFERENCES . . . . .	7
CHARACTERISTICS OF STUDIES . . . . .	15
DATA AND ANALYSES . . . . .	61
Analysis 1.1. Comparison 1 Colloid versus crystalloid (add-on colloid), Outcome 1 Deaths. . . . .	62
Analysis 2.1. Comparison 2 Colloid and hypertonic crystalloid versus isotonic crystalloid, Outcome 1 Deaths. . . . .	65
Analysis 3.1. Comparison 3 Colloid versus hypertonic crystalloid, Outcome 1 Deaths. . . . .	66
APPENDICES . . . . .	66
WHAT'S NEW . . . . .	69
HISTORY . . . . .	69
CONTRIBUTIONS OF AUTHORS . . . . .	70
DECLARATIONS OF INTEREST . . . . .	70
SOURCES OF SUPPORT . . . . .	71
NOTES . . . . .	71
INDEX TERMS . . . . .	71

[Intervention Review]

# Colloids versus crystalloids for fluid resuscitation in critically ill patients

Pablo Perel<sup>1</sup>, Ian Roberts<sup>1</sup>, Katharine Ker<sup>1</sup>

<sup>1</sup>Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, London, UK

Contact address: Pablo Perel, Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. [pablo.perel@lshtm.ac.uk](mailto:pablo.perel@lshtm.ac.uk).

**Editorial group:** Cochrane Injuries Group.

**Publication status and date:** New search for studies and content updated (conclusions changed), published in Issue 2, 2013.

**Review content assessed as up-to-date:** 17 October 2012.

**Citation:** Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. *Cochrane Database of Systematic Reviews* 2013, Issue 2. Art. No.: CD000567. DOI: 10.1002/14651858.CD000567.pub6.

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Colloid solutions are widely used in fluid resuscitation of critically ill patients. There are several choices of colloid, and there is ongoing debate about the relative effectiveness of colloids compared to crystalloid fluids.

### Objectives

To assess the effects of colloids compared to crystalloids for fluid resuscitation in critically ill patients.

### Search methods

We searched the Cochrane Injuries Group Specialised Register (17 October 2012), the Cochrane Central Register of Controlled Trials (*The Cochrane Library*) (Issue 10, 2012), MEDLINE (Ovid) 1946 to October 2012, EMBASE (Ovid) 1980 to October 2012, ISI Web of Science: Science Citation Index Expanded (1970 to October 2012), ISI Web of Science: Conference Proceedings Citation Index-Science (1990 to October 2012), PubMed (October 2012), [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and [www.controlled-trials.com](http://www.controlled-trials.com). We also searched the bibliographies of relevant studies and review articles.

### Selection criteria

Randomised controlled trials (RCTs) of colloids compared to crystalloids, in patients requiring volume replacement. We excluded cross-over trials and trials involving pregnant women and neonates.

### Data collection and analysis

Two review authors independently extracted data and rated quality of allocation concealment. We analysed trials with a 'double-intervention', such as those comparing colloid in hypertonic crystalloid to isotonic crystalloid, separately. We stratified the analysis according to colloid type and quality of allocation concealment.

### Main results

We identified 78 eligible trials; 70 of these presented mortality data.

### Colloids compared to crystalloids

**Albumin or plasma protein fraction** - 24 trials reported data on mortality, including a total of 9920 patients. The pooled risk ratio (RR) from these trials was 1.01 (95% confidence interval (CI) 0.93 to 1.10). When we excluded the trial with poor-quality

allocation concealment, pooled RR was 1.00 (95% CI 0.92 to 1.09). *Hydroxyethyl starch* - 25 trials compared hydroxyethyl starch with crystalloids and included 9147 patients. The pooled RR was 1.10 (95% CI 1.02 to 1.19). *Modified gelatin* - 11 trials compared modified gelatin with crystalloid and included 506 patients. The pooled RR was 0.91 (95% CI 0.49 to 1.72). (When the trials by Boldt et al were removed from the three preceding analyses, the results were unchanged.) *Dextran* - nine trials compared dextran with a crystalloid and included 834 patients. The pooled RR was 1.24 (95% CI 0.94 to 1.65).

### Colloids in hypertonic crystalloid compared to isotonic crystalloid

Nine trials compared dextran in hypertonic crystalloid with isotonic crystalloid, including 1985 randomised participants. Pooled RR for mortality was 0.91 (95% CI 0.71 to 1.06).

### Authors' conclusions

There is no evidence from randomised controlled trials that resuscitation with colloids reduces the risk of death, compared to resuscitation with crystalloids, in patients with trauma, burns or following surgery. Furthermore, the use of hydroxyethyl starch might increase mortality. As colloids are not associated with an improvement in survival and are considerably more expensive than crystalloids, it is hard to see how their continued use in clinical practice can be justified.

## PLAIN LANGUAGE SUMMARY

### Are colloids more effective than crystalloids in reducing death in people who are critically ill or injured?

Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein) to replace lost blood, is used to try to maintain blood pressure and reduce the risk of dying. Blood products, non-blood products or combinations are used, including colloid or crystalloid solutions. Colloids are increasingly used but they are more expensive than crystalloids. This review of trials found no evidence that colloids reduce the risk of dying compared with crystalloids, and one type of colloid (starches) might increase the risk of death.

## BACKGROUND

Fluid resuscitation for hypovolaemia is a mainstay of the medical management of critically ill patients, whether as a result of trauma, burns, major surgery or sepsis. Although some studies (Bickell 1994) have suggested that the timing of volume replacement deserves careful consideration, when it comes to selecting the resuscitation fluid, clinicians are faced with a range of options. At one level the choice is between a colloid or crystalloid solution. Colloids are widely used, having been recommended in a number of resuscitation guidelines and intensive care management algorithms (Armstrong 1994; Vermeulen 1995).

The US Hospital Consortium Guidelines recommend that colloids are used in haemorrhagic shock prior to the availability of blood products, and in non-haemorrhagic shock following an initial crystalloid infusion. However, a 1995 survey of US academic health centres found that the use of colloids far exceeded even the Hospital Consortium recommendations (Yim 1995). Surveys of burn care in the US (Fakhry 1995) and in Australia (Victorian DUAC 1991) found that the use of colloids for resuscitation var-

ied without a set pattern.

The choice of fluid has considerable cost implications. Volume replacement with colloids is considerably more expensive than with crystalloids. Clinical studies have shown that colloids and crystalloids have different effects on a range of important physiological parameters. Because of these differences, all-cause mortality is arguably the most clinically relevant outcome measure in randomised trials comparing the two fluid types.

### Why it is important to do this review

Although there have been previous meta-analyses of mortality in randomised trials comparing colloids and crystalloids (Bisonni 1991; Velanovich 1989), neither of these satisfy the criteria that have been proposed for scientific overviews (Oxman 1994), and they predate most of the trials that have been conducted using synthetic colloids, and hypertonic crystalloid solutions. The purpose of this systematic review is to identify and synthesise all available

unconfounded evidence of the effect on mortality in critically ill patients of colloids compared to crystalloids for volume replacement.

## OBJECTIVES

To assess the effects on mortality of using colloids compared to crystalloids, during fluid resuscitation in critically ill patients.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

Controlled trials in which participants were randomised to treatment groups (colloid or control) on the basis of random allocation. As the comparison between fluid type was in terms of effects on mortality, we excluded randomised cross-over trials.

#### Types of participants

Critically ill patients (excluding neonates and pregnant women) who required volume replacement. We included patients who were critically ill as a result of trauma, burns, undergoing surgery, or had other critical conditions such as complications of sepsis. We excluded preoperative elective surgical patients.

#### Types of interventions

We considered the following colloids: dextran 70, hydroxyethyl starches, modified gelatins, albumin or plasma protein fraction. There is overlap between albumin given for volume replacement and albumin given as a nutritional supplement, and many patients with a critical illness have low serum albumin. Where the trial was of total parenteral nutrition with or without albumin, we excluded it. We included trials where the albumin was given as part of volume replacement guided by colloid osmotic pressure or albumin levels.

The control group received crystalloid (isotonic or hypertonic) for fluid replacement. We included trials in which both groups received blood.

We excluded trials of fluids used for other purposes. For example, we excluded trials of pre-loading in preparation for elective surgery, and trials in patients undergoing fluid loading before cardiopulmonary bypass.

### Types of outcome measures

The principal outcome measure was mortality from all causes, assessed at the end of the follow-up period scheduled for each trial.

### Search methods for identification of studies

We did not restrict the search for trials by date, language or publication status.

#### Electronic searches

We searched the following electronic databases:

- Cochrane Injuries Group Specialised Register (17 October 2012);
- the Cochrane Central Register of Controlled Trials (*The Cochrane Library*) (Issue 10, 2012);
- MEDLINE (OvidSP) 1946 to October, Week 1, 2012;
- EMBASE (OvidSP) 1980 to 2012, Week 41;
- ISI Web of Science: Science Citation Index Expanded (1970 to October 2012);
- ISI Web of Science: Conference Proceedings Citation Index-Science (1990 to October 2012);
- PubMed (October 2012);
- National Research Register (2006, Issue 4).

All search strategies are listed in full in [Appendix 1](#).

#### Searching other resources

We searched the reference lists of all relevant papers and published review articles. We also contacted known trialists to identify any further studies that we may have missed. We searched the online trials registers [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and [www.controlled-trials.com](http://www.controlled-trials.com) for published and unpublished studies.

### Data collection and analysis

The Injuries Group Trials Search Coordinator ran the electronic database searches, collated the results and removed duplicates before passing the list of citations to the lead review author (PP) for screening.

#### Selection of studies

Two review authors independently examined the list of citations for eligibility. We obtained full-text copies of all relevant records and independently assessed whether each met the pre-defined inclusion criteria. We resolved disagreement by discussion.

### Assessment of risk of bias in included studies

We scored allocation concealment as described by [Higgins 2011](#), assigning 'high risk of bias' to poorest quality and 'low risk of bias' to best quality (the presence of solutions in identical containers was only taken to mean adequate concealment if the fluid containers were used sequentially).

- Low risk of bias = trials deemed to have taken adequate measures to conceal allocation (i.e. central randomisation; serially numbered, opaque, sealed envelopes; or other description that contained elements convincing of concealment).
- Unclear = trials in which the authors either did not report an allocation concealment approach at all or reported an approach that did not fall into one of the other categories.
- High risk of bias = trials in which concealment was inadequate (such as alternation or reference to case record numbers or to dates of birth).

We collected but did not score information on blinding and loss to follow-up.

### Data synthesis

As a result of comments on the previous version of this review, we have stratified trials by type of fluid rather than type of original injury.

We calculated risk ratios (RRs) and 95% confidence intervals (CI) for each study using a fixed-effect model. We then inspected each comparison visually for evidence of heterogeneity and performed a Chi<sup>2</sup> test. If there was no evidence of heterogeneity (visually or

with a P value < 0.1) the trials were pooled within each type of fluid, but not combined between type of fluid.

### Sensitivity analysis

We then excluded trials with allocation concealment judged as inadequate and repeated the calculations.

The editorial group is aware that a clinical trial by Professor Joachim Boldt has been found to have been fabricated ([Boldt 2009](#)). As the editors who revealed this fabrication point out ([Reinhart 2011](#); [Shafer 2011](#)), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews that include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author on the conclusions of the review.


## RESULTS

### Description of studies

See: [Characteristics of included studies](#); [Characteristics of excluded studies](#); [Characteristics of ongoing studies](#).

We identified 74 trials meeting the inclusion criteria for study design, participants and interventions ([Figure 1](#)). We were able to obtain mortality data for 67 of these. We have reported details of the included trials in the '[Characteristics of included studies](#)' table.

**Figure 1. Study flow diagram: the numbers reflect the most recent update only (17th October 2012)**



Reasons for exclusion of trials were: the use of a cross-over design, testing a resuscitation algorithm, giving the control group oral fluids, the intervention being directed to the maintenance of serum albumin levels, for haemodilution, for fluid loading and for the reduction of intracranial pressure (see 'Characteristics of excluded studies' table).

Of the 67 trials with data on deaths, the quality of allocation concealment was adequate in 13 trials and unclear in most of the others.

There were 56 trials comparing colloid with crystalloid (add-on colloid), 11 trials comparing colloid in hypertonic crystalloid with isotonic crystalloid, and three trials comparing colloid with hypertonic crystalloid.

### Risk of bias in included studies

In general, the design of studies was not well reported. This is reflected in the number of unclear scores given for allocation concealment. We also collected information on blinding and loss to follow-up. Blinding was not well reported and loss to follow-up was generally small. The characteristics for each trial are listed in the 'Characteristics of included studies' table.

## Effects of interventions

### Colloids compared to crystalloids

#### Albumin or plasma protein fraction

Twenty-four trials reported data on mortality, including a total of 9920 patients. The pooled RR was 1.01 (95% CI 0.93 to 1.10). When trials by Boldt were removed, the results were unchanged (RR 1.01; 95% CI 0.93 to 1.10). When we excluded the trial with poor-quality allocation concealment (Lucas 1978), pooled RR was 1.00 (95% CI 0.92 to 1.09).

#### Hydroxyethyl starch

Twenty-five trials compared hydroxyethyl starch with crystalloids, including a total of 9147 randomised patients. The pooled RR for mortality was 1.10 (95% CI 1.02 to 1.19). When trials by Boldt were removed, the results were unchanged.

#### Modified gelatin

Eleven trials compared modified gelatin with crystalloid, including a total of 506 randomised patients. The pooled RR for mortality was 0.91 (95% CI 0.49 to 1.72). When trials by Boldt were removed, the results were unchanged.

### Dextran

Nine trials compared dextran with a crystalloid, including a total of 834 randomised patients. The pooled RR for mortality was 1.24 (95% CI 0.94 to 1.65).

### Colloids in hypertonic crystalloid compared to isotonic crystalloid

One trial compared albumin and hypertonic saline with isotonic crystalloid. The RR of mortality was 0.50 (95% CI 0.06 to 4.33). One trial compared 6% hydroxyethyl starch 130/0.4 and hypertonic saline with Ringer's lactate. The RR of mortality was 0.25 (95% CI 0.03 to 2.15).

Nine trials compared dextran in hypertonic crystalloid with isotonic crystalloid, including 1879 randomised patients. The pooled RR of mortality was 0.91 (95% CI 0.79 to 1.06).

### Colloids in isotonic crystalloid compared to hypertonic crystalloid

Three trials compared colloids in isotonic crystalloid with hypertonic crystalloid. In two of these, where the colloid was either gelatin or starch, there were no deaths in either group. In the remaining trial, with 38 patients, there was a RR of death of 7.00 (95% CI 0.39 to 126.93) for use of colloid, based on three deaths in the treatment group and none in the control group.

### Sensitivity analysis

When all trials authored by Professor Boldt (Boldt 1986; Boldt 1993; Boldt 2001; Lang 2001; Lang 2003) were excluded conclusions remain unchanged.

## DISCUSSION

This systematic review synthesises the evidence from RCTs comparing colloid and crystalloid fluid resuscitation across a wide variety of clinical conditions. The review has been updated and extensively revised to take into account the comments made since it was first published in 1997. In particular, several commentators pointed out that it is inappropriate to combine effect estimates from studies of different colloids. For example, it was argued that large molecular weight colloids such as hydroxyethyl starch may be better retained in the vascular compartment than albumin and gelatins, and would therefore be more likely to show a favourable effect on mortality (Gosling 1998). In response to these concerns, the review has been stratified by type of colloid. However, the

pooled RRs fail to show a mortality benefit for resuscitation with any type of colloid.

There is a trend towards a favourable effect on mortality for colloids in hypertonic crystalloid, compared to isotonic crystalloids. Nevertheless, the results are compatible with the play of chance.

Common to all meta-analyses, this systematic review may have included studies whose interventions and patient characteristics are sufficiently incomparable that the calculation of a summary effect measure may be questioned. The resuscitation regimen differed between trials. Some trials randomised participants to an initial quantity of colloid or crystalloid, and then proceeded with some form of standard resuscitation for all participants. Other trials resuscitated with the allocated fluid to pre-determined end points, either resuscitation end points, or in the case of trauma, until corrective surgery. In addition, the type of colloid or crystalloid, the concentration, and the protocol to determine the quantity of fluid varied. Despite these differences, all participants were in need of volume replacement, and we believe that this variation in the intervention would have an impact on the size of the effect, rather than on its direction.

As regards the effects of albumin versus crystalloid, most of the information (as indicated by the weighting in the meta-analysis) was provided by the SAFE (Saline versus Albumin Fluid Evaluation) trial (SAFE 2004) a large, well conducted, and low risk of bias trial. The pooled RR for death with albumin in this updated meta-analysis is 1.01 (95% CI 0.93 to 1.10).

As for hydroxyethyl starch, the updated meta-analysis provides a more precise estimate of its effect on mortality since it includes many thousands of patients and the number of deaths is large. Furthermore, the two studies that contribute 80% of the weight in the meta-analysis (Myburgh 2012; Perner 2012) were of high methodological quality with a low risk of bias. The pooled relative risk of death with hydroxyethyl starch is 1.10 (95% CI 1.02 to 1.19) suggesting that a mortality reduction is highly unlikely and that there may be an increase in the risk of death.

The results of this updated meta-analysis have important policy implications. There is still no evidence that colloids are superior to crystalloids as a treatment for intravascular volume resuscitation in critically ill patients, and some of them may even increase mortality. In addition, colloids are considerably more expensive than crystalloids. The economic opportunity cost of ongoing colloid use is likely to be considerable, and for this reason the ongoing use of colloids is unjustified.

## AUTHORS' CONCLUSIONS

### Implications for practice

There is no evidence from randomised controlled trials that resuscitation using colloids compared with crystalloids reduces the risk of death in patients with trauma, burns or following surgery. The use of hydroxyethyl starch might even increase mortality. Since colloid use is not associated with improved survival and colloids are considerably more expensive than crystalloids, it is hard to see how their continued use in clinical practice can be justified.

### Implications for research

Further clinical trials of colloid use need to justify carefully the potential for patient benefit.

## ACKNOWLEDGEMENTS

We acknowledge the contribution of Phil Alderson, Frances Bunn, Paul Chinnock, Gillian Schierhout and Mia Pearson who were authors of earlier versions of this review.

We would like to acknowledge the Intensive Care National Audit and Research Network in London (UK), for assistance with identification of trials for this review.

We thank Dr. Frank M. Brunkhorst for providing the Supplementary Appendix to the paper Brunkhorst 2008.

## REFERENCES

### References to studies included in this review

#### Boldt 1986 *{published data only}*

Boldt J, von Bormann B, Kling D, Borner U, Mulch J, Hempelmann G. Volume replacement with a new hydroxyethyl starch preparation (3 percent HES 200/0.5) in heart surgery [Volumenersatz mit einem neuen hydroxyethylstarke – preparat (3% HAS 200/0.5) in der herzchirurgie]. *Infusionstherapie und Klinische Ernährung* 1986;13(3):145–51.

#### Boldt 1993 *{published data only}*

Boldt J, Knothe C, Zickmann B, Andres P, Dapper F, Hempelmann G. Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. *Anesthesia and Analgesia* 1993;76(6):1185–90.

#### Boldt 2001 *{published data only}*

Boldt J, Suttner S, Huttner I, Kumle B, Piper S, Krumholz W. Are costs of a crystalloid-based volume replacement regimen lower than of a colloid-based volume replacement

- strategy. *Infusion Therapy and Transfusion Medicine* 2001; **28**:144–9.
- Boutros 1979** *{published data only}*  
Boutros AR, Ruess R, Olson L, Hoyt JL, Baker WH. Comparison of hemodynamic, pulmonary, and renal effects of use of three types of fluids after major surgical procedures on the abdominal aorta. *Critical Care Medicine* 1979;**7**(1): 9–13.
- Bowser-Wallace 1986** *{published data only}*  
Bowser-Wallace BH, Caldwell FT Jr. A prospective analysis of hypertonic lactated saline v. Ringer's lactate-colloid for the resuscitation of severely burned children. *Burns* 1986; **12**(6):402–9.
- Brunkhorst 2008** *{published and unpublished data}*  
\* Brunkhorst M. Supplementary Appendix. Provided from Dr. Brunkhorst on 26 March 2009.  
Brunkhorst M, Engel C, Bloos F. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *New England Journal of Medicine* 2008;**358**:125–39.
- Bulger 2011** *{published data only}*  
Bulger EM, May S, Kerby JD, Emerson S, Stiell IG, Schreiber MA, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. *Annals of Surgery* 2011;**253**(3):431–41.
- Chavez-Negrete 1991** *{published data only}*  
Chavez-Negrete A, Lajluf Cruz S, Frati Munari A, Perches A, Argulero R. Treatment of hemorrhagic shock with intraosseous or intravenous infusion of hypertonic saline dextran solution. *European Surgical Research* 1991;**23**(2): 123–9.
- Cifra 2003** *{published data only}*  
Cifra HL, Velasco JNJ. A comparative study of the efficacy of 6% Haes-Steril and Ringer's lactate in the management of dengue shock syndrome 555. *Critical Care & Shock* 2003;**6**: 95–100.
- Cooper 2006** *{published data only}*  
Cooper AB, Cohn SM, Zhang HS, Hanna K, Stewart TE, Slutsky AS. Five percent albumin for adult burn shock resuscitation: lack of effect on daily multiple organ dysfunction score. *Transfusion* 2006;**46**(1):80–9.
- Dawidson 1991** *{published data only}*  
Dawidson IJ, Willms CD, Sandor ZF, Coopender LL, Reisch JS, Fry WJ. Ringer's lactate with or without 3% dextran-60 as volume expanders during abdominal aortic surgery. *Critical Care Medicine* 1991;**19**(1):36–42.
- Dehne 2001** *{published data only}*  
Dehne MG, Muhling J, Sablotzki A, Dehn K-L, Sucke N, Hempelmann G. Hydroxyethyl starch (HES) does not directly affect renal function in patients with no prior renal impairment. *Journal of Clinical Anaesthesia* 2001;**13**(2): 103–11.
- Du 2011** *{published data only}*  
Du XJ, Hu WM, Xia Q, Huang ZW, Chen GY, Jin XD, et al. Hydroxyethyl starch resuscitation reduces the risk of intra-abdominal hypertension in severe acute pancreatitis. *Pancreas* 2011;**40**(8):1220–5.
- Dubin 2010** *{published data only}*  
Dubin A, Pozo MO, Casabella CA, Murias G, Pálizas F, Moseinco MC, et al. Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients. *Journal of Critical Care* 2010;**25**(4): 659.e1–8.
- Eleftheriadis 1995** *{published data only}*  
Eleftheriadis S, Sedemund-Adib B, Klotz K-F, Hubner N, Kuppe H. Volume replacement after cardiac surgery: comparison of Ringer, HES 6% and Gelatine 3.5%. *Intensive Care Medicine* 1995;**21**(suppl 1):S216.
- Ernest 1999** *{published data only}*  
Ernest D, Belzberg A, Dodek P. Distribution of normal saline and 5% albumin infusions in septic patients. *Critical Care Medicine* 1999;**27**(1):46–50.
- Evans 1996** *{published and unpublished data}*  
Evans PA, Garnett M, Boffard K, Kirkman E, Jacobson BF. Evaluation of the effect of colloid (Haemaccel) on the bleeding time in the trauma patient. *Journal of the Royal Society of Medicine* 1996;**89**(2):101–4.
- Evans 2003** *{published data only}*  
Evans PA, Heptinstall S, Crowhurst EC, Davies T, Glenn JR, Madira W, et al. Prospective double-blind randomized study of the effects of four intravenous fluids on platelet function and hemostasis in elective hip surgery. *Journal of Thrombosis and Haemostasis* 2003;**1**:2140–8.
- Fries 2004** *{published data only}*  
Fries D, Streif W, Margreiter J, Klingler A, Kuhbacher G, Schobersberger W, et al. The effects of perioperatively administered crystalloids and colloids on concentrations of molecular markers of activated coagulation and fibrinolysis. *Blood Coagulation & Fibrinolysis* 2004;**15**:213–9.
- Gallagher 1985** *{published data only}*  
Gallagher JD, Moore RA, Kerns D, Jose AB, Botros SB, Flicker S, et al. Effects of colloid or crystalloid administration on pulmonary extravascular water in the postoperative period after coronary artery bypass grafting. *Anesthesia and Analgesia* 1985;**64**(8):753–8.
- Goodwin 1983** *{published data only}*  
Goodwin CW, Dorethy J, Lam V, Pruitt BA Jr. Randomized trial of efficacy of crystalloid and colloid resuscitation on hemodynamic response and lung water following thermal injury. *Annals of Surgery* 1983;**197**(5):520–31.
- Grundmann 1982** *{published data only}*  
Grundmann R, Heistermann S. Postoperative albumin infusion therapy based on colloid osmotic pressure. A prospectively randomized trial. *Archives of Surgery* 1985; **120**(8):911–5.  
Grundmann R, Meyer H. The significance of colloid osmotic pressure measurement after crystalloid and colloid infusions. *Intensive Care Medicine* 1982;**8**(4):179–86.
- Guidet 2012** *{published data only}*  
Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M,

- Heininger A, Van Aken H. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. *Critical Care* 2012;**16**(3):R94.
- Guo 2003** *{published data only}*  
Guo XY, Xu ZH, Ren HZ, Luo AL, Huang YG, Ye TH. Effect of volume replacement with hydroxyethyl starch solution for blood loss on splanchnic oxygenation in patients undergoing cytoreductive surgery for ovarian carcinoma. *Zhonghua Yi Xue Za Zhi* 2003;**83**:114–7.
- Hall 1978** *{published data only}*  
Hall K, Sorensen B. The treatment of burn shock. *Scandinavian Journal of Plastic and Reconstructive Surgery* 1973;**7**:67–73.  
Hall K, Sorensen B. The treatment of burns shock. In: Vrabec R, Konickova L, Moserova J editor(s). *Basic problems in burns*. Berlin: Springer-Verlag, 1975.  
Hall KV, Sorensen B. The treatment of burn shock: results of a 5-year randomized, controlled clinical trial of dextran 70 v Ringer lactate solution. *Burns* 1978;**5**(1):107–12.
- Hartmann 1993** *{published data only}*  
Hartmann M, Jonsson K, Zederfeldt B. Effects of dextran and crystalloids on subcutaneous oxygen tension and collagen accumulation. A randomized study in surgical patients. *European Surgical Research* 1993;**25**:270–7.
- James 2011** *{published data only}*  
James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). *British Journal of Anaesthesia* 2011;**107**(5):693–702.
- Jelenko 1978** *{published data only}*  
Jelenko C 3rd. Fluid therapy and the HALFD method. *Journal of Trauma* 1979;**19**(11 Suppl):866–7.  
Jelenko C 3rd, Solenberger RI, Wheeler ML, Callaway BD. Shock and resuscitation. III. Accurate refractometric COP determinations in hypovolemia treated with HALFD. *JACEP* 1979;**8**(7):253–6.  
Jelenko C 3rd, Wheeler ML, Callaway BD, Divilio LT, Bucklen KR, Holdredge TD. Shock and resuscitation. II: Volume repletion with minimal edema using the “HALFD” (Hypertonic Albuminated Fluid Demand) regimen. *JACEP* 1978;**7**(9):326–33.  
Jelenko C 3rd, Williams JB, Wheeler ML, Callaway BD, Fackler VK, Albers CA, et al. Studies in shock and resuscitation, I: use of a hypertonic, albumin-containing, fluid demand regimen (HALFD) in resuscitation. *Critical Care Medicine* 1979;**7**(4):157–67.
- Karanko 1987** *{published data only}*  
Karanko M, Klossner J, Laksonen V. Restoration of volume by crystalloid versus colloid after coronary artery bypass: haemodynamics, lung water, oxygenation and outcome. *Critical Care Medicine* 1987;**15**:559–66.
- Lang 2001** *{published data only}*  
Lang K, Boldt J, Suttner S, Haisch G. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. *Anesthesia and Analgesia* 2001;**93**(2):405–9.
- Lang 2003** *{published data only}*  
Lang K, Suttner S, Boldt J, Kumle B, Nagel D. Volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing major abdominal surgery. *Canadian Journal of Anaesthesia* 2003;**50**:1009–16.
- Lee 2011** *{published data only}*  
Lee JS, Ahn SW, Song JW, Shim JK, Yoo KJ, Kwak YL. Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery. *Circulation Journal* 2011;**75**(10):2397–402.
- Ley 1990** *{published data only}*  
Ley SJ, Miller K, Skov P. Crystalloid versus colloid fluid therapy after cardiac surgery. *Clinical Studies in Cardiac Care* 1990;**19**(1):31–40.
- Lowe 1977** *{published data only}*  
Lowe RJ, Moss GS, Jilek J, Levine HD. Crystalloid versus colloid in the etiology of pulmonary failure after trauma - a randomized trial in man. *Critical Care Medicine* 1979;**7**(3):107–12.  
Lowe RJ, Moss GS, Jilek J, Levine HD. Crystalloid vs colloid in the etiology of pulmonary failure after trauma: a randomized trial in man. *Surgery* 1977;**1**(6):676–83.  
Moss GS, Lowe RJ, Jilek J, Levine HD. Colloid or crystalloid in the resuscitation of hemorrhagic shock: a controlled clinical trial. *Surgery* 1981;**89**(4):434–8.
- Lu 2012** *{published data only}*  
Lu J, Zhao HY, Liu F, An YZ. The influence of lactate Ringer solution versus hydroxyethyl starch on coagulation and fibrinolytic system in patients with septic shock. *Chinese Critical Care Medicine* 2012;**24**(1):38–41.
- Lucas 1978** *{published data only}*  
Clift DR, Lucas CE, Ledgerwood AM, Sardesai V, Kithier K, Grabow D. The effect of albumin resuscitation for shock on the immune response to tetanus toxoid. *Journal of Surgical Research* 1982;**32**:449–52.  
Johnson SD, Lucas CE, Gerrick SJ, Ledgerwood AM, Higgins R. Altered coagulation after albumin supplements for treatment of oligoemic shock. *Archives of Surgery* 1979;**114**:379–83.  
Lucas CE, Bouwman DL, Ledgerwood AM, Higgins R. Differential serum protein changes following supplemental albumin resuscitation for hypovolemic shock. *Journal of Trauma* 1980;**20**(1):47–51.  
Lucas CE, Weaver D, Higgins RF, Ledgerwood AM, Johnson SD, Bouwman DL. Effects of albumin versus non-albumin resuscitation on plasma volume and renal excretory function. *Journal of Trauma* 1978;**18**:565–70.  
Weaver DW, Ledgerwood AM, Lucas CE, Higgins R, Bouwman DL, Johnson SD. Pulmonary effects of albumin

- resuscitation for severe hypovolaemic shock. *Archives of Surgery* 1978;**113**:387–92.
- Maitland 2005** *{published data only}*  
Maitland K, Pamba A, English M, Peshu N, Marsh K, Newton C, et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. *Clinical Infectious Diseases* 2005;**40**(4):538–45.
- Maitland 2011** *{published data only}*  
Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, et al. Mortality after fluid bolus in African children with severe infection. *New England Journal of Medicine* 2011;**364**(26):2483–95.
- Mattox 1991** *{published data only}*  
Maningas PA, Mattox KL, Pepe PE, Jones RL, Feliciano DV, Burch JM. Hypertonic saline-dextran solutions for the prehospital management of traumatic hypotension. *American Journal of Surgery* 1989;**157**(5):528–33.  
Mattox KL, Maningas PA, Moore EE, Mateer JR, Marx JA, Aprahamian C, et al. Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The U.S.A. Multicenter Trial. *Annals of Surgery* 1991;**213**(5):482–91.
- Mazher 1998** *{published data only}*  
Mazher R, Samenesco A, Royston D, Rees A. Cardiopulmonary effects of 7.2% saline solution compared with gelatin infusion in the early postoperative period after coronary artery bypass grafting. *Journal of Thoracic and Cardiovascular Surgery* 1998;**115**(1):178–87.
- McIntyre 2008** *{published data only}*  
McIntyre LA, Fergusson D, Cook DJ, Rankin N, Dhingra V, Granton J, et al. Fluid resuscitation in the management of early septic shock (FINISS): a randomized controlled feasibility trial [Journal canadien d'anesthésie]. *Canadian Journal of Anaesthesia* 2008;**55**(12):819–26.
- McNulty 1993** *{published data only}*  
McNulty SE, Sharkey SJ, Asam B, Lee JH. Evaluation of STAT-CRIT hematocrit determination in comparison to coulter and centrifuge: the effects of isotonic hemodilution and albumin administration. *Anesthesia and Analgesia* 1993;**76**:830–4.
- Metildi 1984** *{published data only}*  
Metildi LA, Shackford SR, Virgilio RW, Peters RM. Crystalloid versus colloid in fluid resuscitation of patients with severe pulmonary insufficiency. *Surgery, Gynecology and Obstetrics* 1984;**158**(3):207–12.
- Modig 1983** *{published data only}*  
Modig J. Advantages of dextran 70 over Ringer acetate solution in shock treatment and in prevention of adult respiratory distress syndrome. A randomized study in man after traumatic-haemorrhagic shock. *Resuscitation* 1983;**10**(4):219–26.  
Modig J. Effectiveness of dextran 70 versus Ringer's acetate in traumatic shock and adult respiratory distress syndrome. *Critical Care Medicine* 1986;**14**(5):454–7.
- Moretti 2003** *{published data only}*  
Moretti EW, Robertson KM, El Moalem H, Gan TJ. Intraoperative colloid administration reduces postoperative nausea and vomiting and improves postoperative outcomes compared with crystalloid administration. *Anesthesia and Analgesia* 2003;**96**:611–7.
- Myburgh 2012** *{published data only}*  
Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA, the CHEST Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. *The New England Journal of Medicine* 2012;**367**(20):1901–11.
- Nagy 1993** *{published data only}*  
Nagy KK, Davis J, Duda J, Fildes J, Roberts R, Barrett J. A comparison of pentastarch and lactated Ringer's solution in the resuscitation of patients with hemorrhagic shock. *Circulatory Shock* 1993;**40**(4):289–94.
- Ngo 2001** *{published data only}*  
Ngo NT, Cao XT, Kneen R, Wills B, Nguyen VM, Nguyen TQ, et al. Acute management of dengue shock syndrome: a randomised double-blind comparison of 4 intravenous fluid regimes in the first hour. *Clinical Infectious Diseases* 2001;**32**(2):204–13.
- Nielsen 1985** *{published data only}*  
Nielsen OM, Engell HC. Extracellular fluid volume and distribution in relation to changes in plasma colloid osmotic pressure after major surgery. A Randomised Study. *Acta Chirurgica Scandinavica* 1985;**151**:221–5.
- Perner 2012** *{published data only}*  
Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis. *The New England Journal of Medicine* 2012;**367**(2):124–34.
- Pockaj 1994** *{published data only}*  
Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM, et al. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. *Journal of Immunotherapy* 1994;**15**(1):22–8.
- Prien 1990** *{published data only}*  
Prein T, Backhaus N, Pelster F, Pircher W, Buente H, Lawin P. Effect of intraoperative fluid administration and colloid osmotic pressure on the formation of intestinal edema during gastrointestinal surgery. *Journal of Clinical Anesthesia* 1990;**2**:317–23.
- Rackow 1983** *{published data only}*  
Haupt, MT, Rackow, EC. Colloid osmotic pressure and fluid resuscitation with hetastarch, albumin, and saline solutions. *Critical Care Medicine* 1982;**10**(3):159–62.  
Kaufman BS, Rackow EC, Falk JL. Fluid resuscitation in circulatory shock. Colloids versus crystalloids. *Current*

- Studies in Hematology and Blood Transfusion* 1986;**53**: 186–98.
- Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt MT, et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. *Critical Care Medicine* 1983;**11**(11): 839–50.
- Rocha e Silva 1994** *{published data only (unpublished sought but not used)}*
- Rocha e Silva M, Poli de Figueiredo LF. Hypertonic-hyperoncotic saline solution for the treatment of post-traumatic hypotension in the emergency room. The Brazilian multi-center trial. SALT 6. International Conference on Hypertonic Resuscitation, Teton Village. 2–3 June 1994.
- SAFE 2004** *{published data only}*
- The SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *New England Journal of Medicine* 2004;**350**(22):2247–56.
- Shah 1977** *{published data only}*
- Shah DM, Broner BD, Dutton RE, Newell JC, Powers SR. Cardiac output and pulmonary wedge pressure. Use for evaluation of fluid replacement in trauma patients. *Archives of Surgery* 1977;**112**:1161–8.
- Shires 1983** *{published data only}*
- Shires G, Peitzman A, Albert S, Illner H, Silane M, Perry M, et al. Response of extravascular lung water to intraoperative fluids. *Annals of Surgery* 1983;**197**:515–8.
- Sirieux 1999** *{published data only}*
- Sirieux D, Hongnat J-M, Delayance S, D'Attellis N, Vicaut E, Berribi A, et al. Comparison of the acute haemodynamic effects of hypertonic or colloid infusions immediately after mitral valve repair. *Critical Care Medicine* 1999;**27**: 2159–65.
- Skillman 1975** *{published data only}*
- Skillman JJ, Restall DS, Salzman EW. Randomized trial of albumin vs. electrolyte solutions during abdominal aortic operations. *Surgery* 1975;**78**(3):291–303.
- Tollofsrud 1995** *{published data only}*
- Tollofsrud S, Svennevig JL, Breivik H, Kongsgaard U, Ozer M, Hysing E, et al. Fluid balance and pulmonary functions during and after coronary artery bypass surgery: Ringer's acetate compared with dextran, polygeline, or albumin. *Acta Anaesthesiologica Scandinavica* 1995;**39**:671–7.
- Tollofsrud 1998** *{published data only}*
- Tollofsrud S, Noddeland H. Hypertonic saline and dextran after coronary artery surgery mobilises fluid excess and improves cardiorespiratory functions. *Acta Anaesthesiologica Scandinavica* 1998;**42**:154–61.
- Upadhyay 2004** *{published data only}*
- Upadhyay M, Singhi S, Murlidharan J, Kaur N, Majumdar S. Randomized evaluation of fluid resuscitation with crystalloid (saline) and colloid (polymer from degraded gelatin in saline) in pediatric septic shock. *Indian Pediatrics* 2004;**42**(3):223–31.
- Vassar 1990** *{published data only}*
- Vassar MJ, Perry CA, Holcroft JW. Analysis of potential risks associated with 7.5% sodium chloride resuscitation of traumatic shock. *Archives of Surgery* 1990;**125**(10): 1309–15.
- Vassar 1991** *{published data only}*
- Holcroft JW, Vassar MJ, Turner JE, Derlet RW, Kramer GC. 3% NaCl and 7.5% NaCl/dextran 70 in the resuscitation of severely injured patients. *Annals of Surgery* 1987;**206**(3): 279–88.
- Vassar MJ, Perry CA, Gannaway WL, Holcroft JW. 7.5% sodium chloride/dextran for resuscitation of trauma patients undergoing helicopter transport. *Archives of Surgery* 1991; **126**(9):1065–72.
- Vassar 1993a** *{published data only}*
- Vassar MJ, Perry CA, Holcroft JW. Prehospital resuscitation of hypotensive trauma patients with 7.5% NaCl versus 7.5% NaCl with added dextran: a controlled trial. *Journal of Trauma* 1993;**34**(5):622–32.
- Vassar 1993b** *{published data only}*
- Vassar MJ, Fischer RP, O'Brien PE, Bachulis BL, Chambers JA, Hoyt DB, et al. A multicenter trial for resuscitation of injured patients with 7.5% sodium chloride. The effect of added dextran 70. The Multicenter Group for the Study of Hypertonic Saline in Trauma Patients. *Archives of Surgery* 1993;**128**(9):1003–11.
- Verheij 2006** *{published data only}*
- Verheij J, van Lingen A, Beishuizen A, Christiaans HM, de Jong JR, Girbes AR, et al. Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery. *Intensive Care Medicine* 2006;**32**(7):1030–8.
- Virgilio 1979** *{published data only}*
- Virgilio RW, Rice CL, Smith DE, James DR, Zarins CK, Hobelmann CF, et al. Crystalloid vs. colloid resuscitation: is one better? A randomized clinical study. *Surgery* 1979;**85** (2):129–39.
- Wahba 1996** *{published data only}*
- Wahba A, Sendtner E, Strotzer M, Wild K, Birnbaum DE. Fluid therapy with Ringer's solution versus Haemaccel following coronary artery bypass surgery. *Acta Anaesthesiologica Scandinavica* 1996;**40**:1227–33.
- Wills 2005** *{published data only}*
- Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. *The New England Journal of Medicine* 2005;**353**:877–89.
- Woittiez 1997** *{published and unpublished data}*
- Hondebrink Y, Jeekel L, Oude Nijhuis J, Woittiez AJJ. Restoration of colloid osmotic pressure in hypoalbuminaemic patients. *Intensive Care Medicine* 1997; **23**(supp 1):S184.
- Wu 2001** *{published data only}*
- Wu J, Huang M, Tang G, Kao W, Shih H, Su C, et al. Hemodynamic response of modified fluid gelatin compared with lactated ringer's solution for volume

expansion in emergency resuscitation of hypovolemic shock patients: preliminary report of a prospective, randomized trial. *World Journal of Surgery* 2001;**25**(5):598–602.

**Younes 1992** {published data only}

Younes RN, Aun F, Accioly CQ, Casale LP, Szajn bok I, Birolini D. Hypertonic solutions in the treatment of hypovolemic shock: a prospective, randomized study in patients admitted to the emergency room. *Surgery* 1992; **111**(4):380–5.

**Younes 1994** {published data only}

Younes R, Aun F, Ching C, Goldenberg D, Franco M, Miura F, et al. Prognostic factors to predict outcome following the administration of hypertonic/hyperoncotic solution in hypovolaemic patients. *Shock* 1997;**7**:79–83. Younes RN, Aun F, Ching C, Goldenberg D, Franco M, Miura F, Santos S, et al. Prognosis following the administration of hypertonic/hyperoncotic solutions in hypovolemic patients. SALT 6. International Conference on Hypertonic Resuscitation. Teton Village. June 2–3 1994. [http://www.dtic.mil/dtic/tr/fulltext/u2/a286110.pdf]

**Younes 1998** {published data only}

Younes R, Yin K, Amino C, Itinoshe M, Rocha e Silva M, Birolini D. Use of pentastarch solution in the treatment of patients with hemorrhagic hypovolemia: randomized phase II study in the emergency room. *World Journal of Surgery* 1998;**22**:2–5.

**Zetterstrom 1981a** {published data only}

Zetterstrom H, Hedstrand U. Albumin treatment following major surgery. I. Effects on plasma oncotic pressure, renal function and peripheral oedema. *Acta Anaesthesiologica Scandinavica* 1981;**25**:125–32.

**Zetterstrom 1981b** {published data only}

Zetterstrom H. Albumin treatment following major surgery. II. Effects on postoperative lung function and circulatory adaptation. *Acta Anaesthesiologica Scandinavica* 1981;**25**: 133–41.

**Zhu 2011** {published data only}

Zhu GC, Quan ZY, Shao YS, Zhao JG, Zhang YT. [The study of hypertonic saline and hydroxyethyl starch treating severe sepsis]. [Chinese] [Zhongguo Wei Zhong Bing Ji Jiu Yi Xue]. Chinese Critical Care Medicine 2011; Vol. 23, issue 3:150–3.

## References to studies excluded from this review

**Artru 1989** {published data only}

Artru F, Philippon B, Flachaire E, Peyrieux JC, Boissel JP, Ferry S, et al. A controlled study of dextran 40: effect on cerebral blood flow and metabolic rates in acute head trauma. *Intensive Care Medicine* 1989;**15**(8):499–504.

**Bocanegra 1966** {published data only}

Bocanegra M, Hinostroza F, Kefalides NA, Markley K, Rosenthal SM. A long-term study of early fluid therapy in severely burned adults. 3. Simultaneous comparison of saline solution alone or combined with plasma. *Journal of the American Medical Association* 1966;**195**(4):268–74.

**Boldt 1996** {published data only}

Boldt J, Heesen M, Padberg W, Martin K, Hempelmann G. The influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients. *Anaesthesia* 1996;**51**:529–35.

**Boldt 2007** {published data only}

Boldt J, Schollhorn T, Munchbach J. A total balanced volume replacement strategy using a new balanced hydroxyethyl starch preparation (6% HES 130/0.42) in patients undergoing major abdominal surgery. *European Journal of Medicine* 2007;**24**:267–75.

**Bothner 1998** {published data only}

Bothner U, Georgieff M, Vogt N. Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/0.5) solution: a randomized, controlled epidemiology study. *Anesthesia and Analgesia* 1998;**86**:850–5.

**Brehme 1993** {published data only}

Brehme S, Keysser G, Turowski A, Schmidt HH. Hemorheologic effects of hydroxyethyl starch 200/0.5, dextran 40, oxypolygelatine and full electrolyte solution over 48 hours [Hamorheologische Wirkungen von Hydroxyethylstarke 200/0.5, Dextran 40, Oxypolygelatine und Vollelektrolytlosung uber 48 Stunden]. *Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete* 1993;**48** (10):506–10.

**Bueno R 2004** {published data only}

Bueno R, Resende AC, Melo R, Neto VA, Stolf NA. Effects of hypertonic saline-dextran solution in cardiac valve surgery with cardiopulmonary bypass. *Annals of Thoracic Surgery* 2004;**77**(2):604–11.

**Chin 2006** {published data only}

Chin Y, Macachor J, Ong KC, Ong BC. A comparison of 5% dextrose in 0.9% normal saline versus non-dextrose-containing crystalloids as the initial intravenous replacement fluid in elective surgery. *Anaesthesia and Intensive Care* 2006;**34**(5):613–7.

**Golub 1994** {published data only}

Golub R, Sorrento JJ Jr, Cantu R Jr, Nierman DM, Moideen A, Stein HD. Efficacy of albumin supplementation in the surgical intensive care unit: a prospective, randomized study. *Critical Care Medicine* 1994;**22**(4):613–9.

**Goslinga 1992** {published data only}

Goslinga H, Eijzenbach V, Heuvelmans JH, van de Nes JC, Kurk RM, Bezemer PD. [Individualized hemodilution in acute brain infarct using a 20% albumin solution and physiological saline solution]. *Nederlands Tijdschrift voor Geneeskunde* 1992;**136**(49):2422–8. Goslinga H, Eijzenbach V, Heuvelmans JH, van der Laan de Vries E, Melis VM, Schmid-Schönbein H, et al. Custom-tailored hemodilution with albumin and crystalloids in acute ischemic stroke. *Stroke* 1992;**23**(2):181–8. Goslinga H, Heuvelmans JH, Schmid Schonbein H. Hemodilution and rehydration in acute ischemic stroke. A preliminary report on the Amsterdam Stroke Study. *Acta Medica Austriaca* 1991;**18**(Suppl 1):41–4.

- Green 2008** *{published data only}*  
Green RS, Hall RI. Con: starches are not preferable to albumin during cardiac surgery: a contrary opinion. *Journal of Cardiothoracic and Vascular Anesthesia* 2008;**22**(3):485–91.
- Greenhalgh 1995** *{published data only}*  
Greenhalgh DG, Housinger TA, Kagan RJ, Rieman M, James L, Novak S, et al. Maintenance of serum albumin levels in pediatric burn patients: a prospective, randomized trial. *Journal of Trauma* 1995;**39**(1):67-73; discussion 73-4.
- Hauser 1980** *{published data only}*  
Hauser CJ, Shoemaker WC, Turpin I, Goldberg SJ. Oxygen transport response to colloids and crystalloids in critically ill surgical patients. *Surgery* 1980;**150**(6):811–6.
- Ko 2007** *{published data only}*  
Ko JS, Kim CS, Cho HS, Choi DH. A randomized trial of crystalloid versus colloid solution for prevention of hypotension during spinal or low-dose combined spinal-epidural anesthesia for elective cesarean delivery. *International Journal of Obstetric Anesthesia* 2007;**16**(1):8–12.
- Krasheninnikov 2007** *{published data only}*  
Krasheninnikov SV, Levit AL, Malkova OG. Effect of various colloidal solutions on pulmonary oxygenizing function in patients with acute lung lesion. *Anestziologiya i Reanimatologiya* 2007;**3**:20–2.
- Lagonidis 1995** *{published data only}*  
Lagonidis D, Magder S. Acute volume loading with colloid vs. crystalloid after coronary artery bypass. *Intensive Care Medicine* 1992;**18**(suppl 2):S225.
- Lange 2011** *{published data only}*  
Lange M, Ertmer C, Van Aken H, Westphal M. Intravascular volume therapy with colloids in cardiac surgery. *Journal of Cardiothoracic and Vascular Anesthesia* 2011;**25**(5):847–55.
- Lobo 2008** *{published data only}*  
Lobo SM, Orrico SR, Queiroz MM, Contrim LM, Cury PM. Comparison of the effects of the lactated Ringer solution with and without hydroxyethyl starch fluid resuscitation on gut edema during severe splanchnic ischemia. *Brazilian Journal of Medical and Biological Research* 2008;**41**(7):634–9.
- Marhofer 1999** *{published data only}*  
Marhofer P, Faryniak B, Oismuller C, Koinig H, Kapral S, Mayer N. Cardiovascular effects of 6% hetastarch and lactated Ringer's solution during spinal anaesthesia. *Regional Anesthesia and Pain Medicine* 1999;**24**:399–404.
- Mittermayr 2007** *{published data only}*  
Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, et al. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. *British Journal of Anaesthesia* 2007;**105**(4):905–17.
- Mittermayr 2008** *{published data only}*  
Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, et al. Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo. *British Journal of Anaesthesia* 2008;**100**(3):307–14.
- Morrison 2011** *{published data only}*  
Morrison LJ, Baker AJ, Rhind SG, Kiss A, MacDonald RD, Schwartz B, et al. The Toronto prehospital hypertonic resuscitation - head injury and multiorgan dysfunction trial: feasibility study of a randomized controlled trial. *Journal of Critical Care* 2011;**26**(4):363–72.
- Niemi 2008** *{published data only}*  
Niemi T, Schramko A, Kuitunen A, Kukkonen S, Suojaranta-Ylinen R. Haemodynamics and Acid-base equilibrium after cardiac surgery: comparison of rapidly degradable hydroxyethyl starch solutions and albumin. *Scandinavian Journal of Surgery* 2008;**97**(3):259–65.
- Nilsson 1980** *{published data only}*  
Nilsson E, Lamke O, Liljedahl SO, Elfstrom K. Is albumin therapy worthwhile in surgery for colorectal cancer?. *Acta Chirurgica Scandinavica* 1980;**146**:619–22.
- Oliviera 2002** *{published data only}*  
Oliviera RP, Weingartner R, Ribas EO, Moraes RS, Friedman G. Acute haemodynamic effects of a hypertonic saline/dextran solution in stable patients with severe sepsis. *Intensive Care Medicine* 2002;**28**(11):1574–81.
- Paton-Gay 2007** *{published data only}*  
Paton-Gay JD, Brindley PG, McDermid RC. Best evidence in critical care medicine: fluid management in acute lung injury: friend or foe?. *Canadian Journal of Anesthesia* 2007;**54**(1):73–5.
- Paul 2003** *{published data only}*  
Paul M, Dueck M, Joachim Herrman H, Holzki J. A randomized, controlled study of fluid management in infants and toddlers during surgery: hydroxyethyl starch 6% (HES 70/0.5) vs lactated Ringer's solution. *Paediatric Anaesthesia* 2003;**13**(7):603–8.
- Rehm 2001** *{published data only}*  
Rehm M, Haller M, Orth V, Kreimeier U, Jacob M, Dressel H, et al. Changes in blood volume and hematocrit during acute preoperative volume loading with 5% albumin or 6% hetastarch solutions in patients before radical hysterectomy. *Anesthesiology* 2001;**95**(4):849–56.
- Steinberg 1989** *{published data only}*  
Steinberg B, Kochs E, Bause H, Schulte am Esch J. Effects of low molecular weight hydroxyethyl starch (HES 40) in comparison with Ringer solution on oxygen tension in skeletal muscles of infected patients. *Anästhesie, Intensivtherapie, Notfallmedizin* 1989;**24**(6):377–81.
- Tiryakioglu 2008** *{published data only}*  
Tiryakioglu O, Yildiz G, Vural H, Goncu T, Ozyazicioglu A, Yavuz S. Hydroxyethyl starch versus Ringer solution in cardiopulmonary bypass prime solutions (a randomized controlled trial). *Journal of Cardiothoracic Surgery* 2008;**3**(45):1–6.

**Tseng 2008** *{published data only}*

Tseng M, Hutchinson Y, Kirkpatrick P. Effects of fluid therapy following aneurysmal subarachnoid haemorrhage: a prospective clinical study. *British Journal of Neurosurgery* 2008;**22**(2):257–68.

**Valetova 2007** *{published data only}*

Valetova VV, Khudenko NV, Sakharova EA, Timerbaev VK. Role of starch preparations in the intraoperative correction of hypovolemia in patients with large-size uterine myomas. *Anesteziologiya i Reanimatologiya* 2007;**2**:31–4.

**van der Heijden 2009** *{published data only}*

van der Heijden M, Verheij J, van Nieuw Amerongen GP, Groeneveld, AB. Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia. *Critical Care Medicine* 2009;**37**(4):1275–81.

**Vercueil 2006** *{published data only}*

Vercueil A, Levett D, Grocott M. Resuscitation fluids in trauma, part II: which fluid should I give?. *Trauma* 2006;**8**(2):111–21.

**Wilkes 2001** *{published data only}*

Wilkes N, Woolf R, Mutch M, Mallett S, Peache T, Stephens R, et al. The effects of balanced versus saline-based heta-starch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. *Anaesthesia and Analgesia* 2001;**93**(4):811–6.

**Woods 1993** *{published data only}*

Woods MS, Kelley H. Oncotic pressure, albumin and ileus: the effect of albumin replacement on postoperative ileus. *The American Surgeon* 1993;**59**:758–63.

## References to ongoing studies

**RASP trial** *{published data only}*

Lactated Ringer Versus Albumin in Early Sepsis Therapy (RASP). Ongoing study May 2012.

## Additional references

**Armstrong 1994**

Armstrong RF, Bullen C, Cohen SL, Singer M, Webb AR. *Critical care algorithms*. Oxford: Oxford University Press, 1994.

**Bickell 1994**

Bickell WH, Wall MJ, Pepe PE, Martin R, Ginger VF, Allen MK, et al. Immediate versus delayed resuscitation for hypotensive patients with penetrating torso injuries. *New England Journal of Medicine* 1994;**331**:1105–9.

**Bisonni 1991**

Bisonni RS, Holtgrave DR, Lawler F, Marley DS. Colloids versus crystalloids in fluid resuscitation: an analysis of randomized controlled trials. *Journal of Family Practice* 1991;**32**(4):387–90.

**Boldt 2009**

Boldt J, Suttner S, Brosch C, Lehmann A, Roehm K, Mengitsu A. Cardiopulmonary bypass priming using a high

dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy. *Anesthesia & Analgesia* 2009;**109**:1752–62.

**Fakhry 1995**

Fakhry SM, Alexander J, Smith D, Meyer AA, Peterson HD. Regional and institutional variation in burn care. *Journal of Burn Care and Rehabilitation* 1995;**16**(1):86–90.

**Gosling 1998**

Gosling P. Newer synthetic colloids should not be abandoned. *BMJ* 1998;**317**:277.

**Higgins 2011**

Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

**Oxman 1994**

Oxman AD, Cook DJ, Guyatt GH. User's guide to the medical literature. VI. How to use an overview. *Journal of the American Medical Association* 1994;**272**:1367–71.

**Reinhart 2011**

Reinhart K, Takala J. Hydroxyethyl starches: what do we still know?. *Anesthesia and Analgesia* 2011;**112**(3):507–11.

**Shafer 2011**

Shafer SL. Shadow of doubt. *Anesthesia and Analgesia* 2011;**112**(3):498–500.

**Velanovich 1989**

Velanovich V. Crystalloid versus colloid fluid resuscitation: a meta-analysis of mortality. *Surgery* 1989;**105**(1):65–71.

**Vermeulen 1995**

Vermeulen LC, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. *Archives of Internal Medicine* 1995;**155**(4):373–9.

**Victorian DUAC 1991**

Subcommittee of the Victorian Drug Usage Advisory Committee. Human albumin solutions: an audit of use in three major metropolitan hospitals. *Medical Journal of Australia* 1991;**154**(10):657–60.

**Yim 1995**

Yim JM, Vermeulen LC, Erstad BL, Matuszewski KA, Burnett DA, Vlasses PH. Albumin and nonprotein colloid solution use in US academic health centers. *Archives of Internal Medicine* 1995;**155**(22):2450–5.

## References to other published versions of this review

**Schierhout 1998**

Schierhout G, Roberts I. Fluid resuscitation with colloids or crystalloid solutions in critically ill patients: a systematic review of randomised controlled trials. *BMJ* 1998;**316**:961–4.

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### Boldt 1986

Methods	RCT, using sealed opaque envelopes Information on allocation concealment was obtained on contact with the authors Blinding and loss to follow-up not mentioned	
Participants	55 patients undergoing elective aorta-coronary bypass surgery Exclusion criteria: ejection fraction < 50% and LVEDP > 15 mmHg	
Interventions	<ol style="list-style-type: none"> <li>1. 300 mL 20% Human albumin solution (n = 15)</li> <li>2. 500 mL 3% HES (n = 13)</li> <li>3. 500 mL 3.5% Gelatin (n = 14)</li> <li>4. No colloid (n = 13)</li> </ol>	
Outcomes	Haemodynamic variables were measured Deaths not reported	
Notes	Follow-up until discharge from ICU	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

#### Boldt 1993

Methods	RCT, allocation concealment by sealed opaque envelopes (information from author) Blinding and loss to follow-up not mentioned	
Participants	75 males undergoing elective aortocoronary bypass grafting, who had a pulmonary capillary WP < 5 mmHg after induction of anaesthesia	
Interventions	<ol style="list-style-type: none"> <li>1. 5% Albumin (n = 15)</li> <li>2. 6% HES, mean molecular weight 450,000 (n = 15)</li> <li>3. 6% HES, mean molecular weight 200,000 (n = 15)</li> <li>4. 3.5% Gelatin (n = 15)</li> <li>5. No colloid (n = 15)</li> </ol> Fluid used through operation and on intensive care postoperatively	
Outcomes	Deaths not reported, author confirmed there were no deaths	
Notes	Follow-up to 1 day	

**Boldt 1993** (Continued)

<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Unclear

**Boldt 2001**

Methods	RCT, using a closed-envelope system
Participants	100 patients undergoing major abdominal surgery
Interventions	<ol style="list-style-type: none"> <li>1. Ringer's lactate (n = 25)</li> <li>2. 6% HES, mean molecular weight 200 kDa, degree of substitution 0.5 (n = 25)</li> <li>3. 6% HES, mean molecular weight 130 kDa, degree of substitution 0.4 (n = 25)</li> <li>4. 4% Modified fluid gelatin, molecular weight 35 kDa (n = 25)</li> </ol>
Outcomes	Deaths Orthostatic problems Haemodynamics and laboratory data Fluid input and output Costs
Notes	Follow-up period unclear

*Risk of bias*

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Unclear

**Boutros 1979**

Methods	RCT ("randomly divided"), method of allocation concealment not described Blinding not mentioned No loss to follow-up
Participants	24 people undergoing major operative procedures on the abdominal aorta
Interventions	<ol style="list-style-type: none"> <li>1. Albumin in 5% dextrose (n = 7)</li> <li>2. 5% Dextrose and Ringer's lactate (n = 8)</li> <li>3. 5% Dextrose in 0.45% saline (n = 9)</li> </ol> Allocated fluids were used on admission to ICU, following surgery, guided by PAWP. Whole blood also given if clinically needed
Outcomes	Deaths reported

**Boutros 1979** (Continued)

Notes	Follow-up to discharge from hospital	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Bowser-Wallace 1986**

Methods	Quasi-RCT, allocation by alternation Blinding not mentioned No loss to follow-up	
Participants	Admitted for burns of 30% or more Age range 5 months to 21 years Excluded if already given more than half calculated daily requirement before reaching hospital	
Interventions	<ol style="list-style-type: none"> <li>1. 2 mL/kg/%burn Ringer's lactate over 24 hours, then 0.5 mL plasmanate/kg/%burn over 24 hours plus 5% dextrose (n = 19)</li> <li>2. 2 mL/kg/%burn hypertonic lactated saline over 24 hours, then 0.6 mL/kg/%burn hypertonic lactated saline over 24 hours plus oral Haldane's solution (n = 19)</li> </ol> IV fluids stopped at 48 hours (n = 19)	
Outcomes	Deaths reported Fluid and electrolytes given, weight, haematocrit	
Notes	Follow-up to 5 days	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	High risk	Inadequate

**Brunkhorst 2008**

Methods	Multicentre, RCT Blinding not mentioned Use of a 2 x 2 factorial, open label study design	
Participants	Critically ill patients with severe sepsis or septic shock of at least 18 years of age. Excluded if onset of symptoms commenced > 24 hours before admission to the ICU, if the symptoms commenced > 12 hours after onset in the ICU or if patient had received more than 1000 mL of HES in the 24 hours before randomisation	

**Brunkhorst 2008** (Continued)

Interventions		
Outcomes	Deaths reported at 28 and 90 days. 90-day mortality rate was cited as it marked the end of the follow-up period	
Notes	-	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Bulger 2011**

Methods	Double-blind RCT	
Participants	15 years or older with hypovolaemic shock (< 70 mmHg SBP or SBP 71 mmHg to < 90 mmHg and HR < 108 bpm)	
Interventions	<ol style="list-style-type: none"> <li>1. 7.5% saline per 6% dextran (n = 220)</li> <li>2. 0.9% saline (n = 376)</li> </ol>	
Outcomes	Primary outcome: 28-day survival Secondary outcomes: fluid and blood requirements, ARDS, MODS and nosocomial infections	
Notes	-	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	All care providers, investigators and patients remained blinded to the treatment assignment

**Chavez-Negrete 1991**

Methods	RCT, allocation by "random numbers" Blinding not mentioned No loss to follow-up	
Participants	Adults admitted to an emergency department with acute GI haemorrhage, SBP ≤ 90 mmHg for up to 1 hour and normal ECG Excluded if pregnant or had renal, cardiac or neurological disease	

**Chavez-Negrete 1991** (Continued)

Interventions	1. Initial infusion of 250 mL 7.5% saline/6% dextran 60 given IV (16 patients) or intraosseous (n = 10) 2. Initial IV infusion of 250 mL Ringer's lactate (n = 23) Resuscitation continued with red cells, 0.9% saline and dextran 40 according to clinical judgement	
Outcomes	Death Haemodynamic variables	
Notes	Follow-up to 24 hours	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Cifra 2003**

Methods	Quasi-RCT (allocation by alternation), allocation concealment not reported Blinding not reported No loss to follow-up	
Participants	27 children with dengue shock syndrome Exclusion criteria included: other severe infection, protein-deficient abnormalities, bleeding diathesis, patients who have been given multiple plasma substitutes	
Interventions	1. 6% Haes-Steril (n = 11) 2. Ringer's lactate (n = 16) 1 patient from group 1 and 3 patients from group 2 were excluded because they needed inotropic support and multiple plasma substitute	
Outcomes	Duration of control of shock Recurrence of shock Length of ICU stay Death not reported as an outcome but they reported that 4 patients died	
Notes	Length of follow-up not reported but all outcomes were in hospital	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Not used

**Cooper 2006**

Methods	Multicentre unblinded controlled trial with stratified block randomisation by centre and mortality prediction at enrolment
Participants	Patients with cutaneous thermal burns of at least 20% TBSA within 12 hours of injury
Interventions	1. Ringer lactate and 5% albumin (n = 19) 2. Ringer lactate (n = 23)
Outcomes	Primary outcome was MODS Mortality was reported
Notes	The trial was suspended due to slow enrolment

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	Patients were allocated to study groups with stratified randomisation with a computer-generated randomisation list and sequentially numbered sealed, opaque envelopes

**Dawidson 1991**

Methods	RCT, allocation by drawing a card from a deck Blinding not mentioned No loss to follow-up
Participants	Adults undergoing elective abdominal aortic surgery No exclusions mentioned
Interventions	1. 3% Dextran 70 in Ringer's lactate (n = 10) 2. IV Ringer's lactate (n = 10) Fluid used during and for 24 hours after operation, guided by haemodynamic variables
Outcomes	Death Volume transfused, weight change, haemodynamic variables
Notes	Follow-up to discharge from hospital

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	High risk	Inadequate

**Dehne 2001**

Methods	RCT, allocation by sealed envelope assignment	
Participants	60 male patients (of ASA physical status 1 or 2) scheduled for middle ear surgery	
Interventions	<ol style="list-style-type: none"> <li>1. Ringer's lactate solution (n = 15)</li> <li>2. 6% HES: molecular weight 200 kDa, degree of substitution 0.5 (n = 15)</li> <li>3. 6% HES: molecular weight 200 kDa, degree of substitution 0.60 to 0.66 (n = 15)</li> <li>4. 6% HES: molecular weight 450 kDa, degree of substitution 0.7 (n = 15)</li> </ol>	
Outcomes	Deaths not stated but 'all' patients discharged 10 to 14 days after surgery; therefore no deaths Central venous pressure Urine output Blood osmolality Urine osmolality	
Notes	Follow-up 2 days	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Du 2011**

Methods	Randomised controlled study	
Participants	Participants had confirmed diagnosis of severe acute pancreatitis. Patients were included within 72 hours after the onset of symptoms	
Interventions	<ol style="list-style-type: none"> <li>1. 6% HES 130/0.4 (n = 20)</li> <li>2. Ringer's lactate (n = 21)</li> </ol>	
Outcomes	Primary outcome was intra-abdominal pressure. They also reported in-hospital mortality, organ complications, inflammatory markers and fluid requirement	
Notes	Patients were excluded if they died within 72 hours after admission	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Dubin 2010**

Methods	RCT	
Participants	Patients with severe sepsis	
Interventions	<ol style="list-style-type: none"> <li>1. 6% HES 130/0.4 (n = 12)</li> <li>2. Normal saline (n = 13)</li> </ol>	
Outcomes	Sublingual microcirculation	
Notes	Data on mortality are not clear from the report	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	sealed envelopes were used

**Eleftheriadis 1995**

Methods	Patients "randomizedly distributed" Blinding not mentioned Unable to assess loss to follow-up	
Participants	Participants were undergoing coronary artery bypass surgery	
Interventions	<ol style="list-style-type: none"> <li>1. 6% HES</li> <li>2. 3.5% Gelatin</li> <li>3. Ringer's lactate</li> </ol> Allocated fluid was used in the postoperative period only guided by mean arterial pressure	
Outcomes	Deaths were not reported Haemodynamic variables	
Notes	Follow-up period unspecified	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Ernest 1999**

Methods	RCT, allocation concealment not described No blinding No loss to follow-up mentioned	
Participants	Patients with a clinical diagnosis of sepsis	
Interventions	1. 5% Albumin (n = 9) 2. 0.9% Saline (n = 9) Volume of infusion guided by PAWP	
Outcomes	Haemodynamic variables and volume measurements Deaths not reported	
Notes	Follow-up to immediately after infusion	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Evans 1996**

Methods	Quasi-randomised trial, allocation by day of the week Blinding not mentioned No loss to follow-up	
Participants	Aged $\geq 16$ years, admitted with trauma to an emergency centre within 2 hours after injury, only crystalloid as a pre-hospital infusion Excluded if had underlying illness likely to affect clotting	
Interventions	1. IV Haemaccel (n = 11) 2. IV Ringer's lactate (n = 14) Fluid was used until vital signs were stable	
Outcomes	Deaths from author Clotting variables	
Notes	Follow-up period unspecified	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	High risk	Inadequate

**Evans 2003**

Methods	RCT, allocation concealment not reported Blinding methods not reported Loss to follow-up not reported	
Participants	55 patients undergoing primary unilateral total hip replacement Exclusion criteria: pre-existing defect in platelet function or on aspirin that could not be stopped for 2 weeks prior to the operation	
Interventions	<ol style="list-style-type: none"> <li>1. 4.5% Albumin (n = 13)</li> <li>2. Gelofusine (n = 14)</li> <li>3. Haemaccel (n = 14)</li> <li>4. 0.9% Saline (n = 14)</li> </ol>	
Outcomes	Haemostatic parameters Death not reported	
Notes	Length of follow-up not reported but all outcomes were in-hospital	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Fries 2004**

Methods	RCT, patients "randomly" received crystalloid or colloids Method of allocation concealment not reported Blinding not reported Loss to follow-up not reported	
Participants	60 patients undergoing knee replacement surgery Exclusion criteria: contraindication for regional anaesthesia, known allergies or haemostatic disorders	
Interventions	<ol style="list-style-type: none"> <li>1. HES (n = 20)</li> <li>2. Modified gelatin (n = 20)</li> <li>3. Ringer's solution (n = 20)</li> </ol> Groups 1 and 2 also received a basis of Ringer's solution infusion	
Outcomes	Coagulation parameters Death not reported	
Notes	Length of follow-up not reported but all outcomes were in-hospital measures	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>

**Fries 2004** (Continued)

Allocation concealment (selection bias)	Unclear risk	Unclear
---	--------------	---------

**Gallagher 1985**

Methods	RCT, method of allocation concealment not described. Author contacted - allocation concealment by computerised system - patient details were entered before treatment assignment was revealed Blinding not mentioned No loss to follow-up
Participants	Patients after coronary artery bypass graft surgery Exclusion criteria: patients with significant left main coronary artery stenosis, poor left ventricular function or poor pulmonary function
Interventions	1. IV 5% albumin (n = 5) 2. IV 6% HES (n = 5) 3. IV Ringer's lactate (n = 5) Fluid used from admission to ICU post operation, guided by PAWP. RBC given if needed
Outcomes	Deaths were not reported. Author contacted and confirmed that there were no deaths in any group Haemodynamic data
Notes	Follow-up to 1 day

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	Adequate

**Goodwin 1983**

Methods	RCT, assigned by "random numbers table", method of allocation concealment unclear Blinding not mentioned No loss to follow-up
Participants	79 previously healthy young adults admitted with burns No exclusion criteria reported
Interventions	1. 2.5% Albumin in Ringer's lactate (n = 40) 2. Ringer's lactate (n = 39) Fluids on day 1 guided by haemodynamic variable. On day 2, given at 0.3 to 0.5 mL/kg/%burn, then 5% dextrose

**Goodwin 1983** (Continued)

Outcomes	Deaths reported Pulmonary oedema Infections	
Notes	Follow-up to discharge from hospital	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Grundmann 1982**

Methods	RCT, method of allocation concealment unclear Blinding not mentioned No loss to follow-up	
Participants	20 people undergoing partial gastrectomy The average age was 50 years (range 19 to 84 years) No exclusion criteria reported	
Interventions	1. Colloid group received human albumin solution (n = 14) 2. Details of crystalloid were not reported (n = 6) Allocated fluid was continued for 4 days after operation	
Outcomes	Deaths reported Volumes of fluid given Haemodynamic variables	
Notes	Follow-up to discharge from hospital	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Guidet 2012**

Methods	RCT Double blind Sequence generation not reported Two arms were identical in appearance, labelled with randomisation numbers 1 outcome from each group missing at day 90
Participants	196 patients aged $\geq 18$ years, who required fluid resuscitation, and who had clinically defined severe sepsis Exclusion criteria: Known serum creatinine $>3.39$ mg/d, Anuria lasting more than 8 hours despite fluid resuscitation, Requirement for renal support Setting: Germany and France
Interventions	1. 6% HES 130/0.4 (n=100) 2. sodium chloride (NaCl 0.9%) (n=96)
Outcomes	The primary endpoint was the amount of study drug required to achieve initial HDS The secondary objectives were time taken to achieve initial HDS, total quantity of study drug infused, length of stay (LOS) in the ICU, Sequential Organ Failure Assessment (SOFA) score and kidney function
Notes	

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	The investigational and control drugs were identical in appearance and packaging, and were labeled with randomization numbers using a blinding methodology

**Guo 2003**

Methods	RCT, allocation concealment not reported Blinding not reported No loss to follow-up reported
Participants	42 patients undergoing elective cytoreductive surgery for ovarian cancer Exclusion criteria: preoperative anaemia, allergic response to HES or perioperative administration of cardiovascular agents 2 patients randomised but excluded because of use of cardiovascular agents
Interventions	1. Ringer's lactate (n = 20) 2. 6% HES (n = 20)
Outcomes	Splanchnic perfusion Death not reported but in results authors mentioned that "all patients were discharged"

**Guo 2003** (Continued)

Notes	Follow-up to discharge from hospital	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Hall 1978**

Methods	Quasi-RCT (participants were stratified by age, extent of burn and aetiology, and then allocated by alternation) Blinding not mentioned No loss to follow-up	
Participants	Burns covering > 10% of the body surface (for children), and > 15% of the body surface (for adults) No exclusions mentioned	
Interventions	<ol style="list-style-type: none"> <li>1. 120 mL/%burn IV 6% dextran 70 in 0.9% saline over 48 hours plus oral water or IV 5% dextrose for 'metabolic requirements' (n = 86)</li> <li>2. 4 mL/kg/%burn IV Ringer's lactate over 24 hours, then 10% of initial body weight of fluid over 24 hours plus oral water (n = 86)</li> </ol>	
Outcomes	Death Fluid given, haemodynamic variables	
Notes	Follow-up to discharge from hospital	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	High risk	Inadequate

**Hartmann 1993**

Methods	RCT, method of allocation unclear Blinding not mentioned No loss to follow-up	
Participants	Adults undergoing major abdominal surgery Exclusion criteria: cardiorespiratory dysfunction, uraemia, diabetes, taking steroids, anti-coagulants or diuretics	

**Hartmann 1993** (Continued)

Interventions	1. IV Dextran 70 in saline (concentration not given) with 2.5% dextrose (n = 15) 2. IV Saline (concentration not given) with 2.5% dextrose (n = 14) Both groups given red cells, plasma, dextran 70 and crystalloids during the operation as decided by the clinician. Postoperative fluids according to the trial group guided by tissue oxygen tension to the end of resuscitation	
Outcomes	Death not reported Fluid given, haemodynamic variables	
Notes	Follow-up to 7 days	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**James 2011**

Methods	RCT Double-blind	
Participants	Patients with blunt or penetrating trauma requiring more than 3 L volume resuscitation (blunt and penetrating trauma patients were randomised separately)	
Interventions	1. HES 130/0.4, penetrating trauma (n = 36) 2. 0.9% Saline, penetrating trauma (n = 34) 3. HES 130/0.4, blunt trauma (n = 22) 4. 0.9% Saline, blunt trauma (n = 23)	
Outcomes	Primary outcomes were the volumes of first fluid needed in the first 24 hours, and normal GI function by day 5	
Notes	Mortality was not reported on the main publication but it was available from an author's reply	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	Plastic bags with concealed label were randomly selected and placed sequentially in a warming cabinet

**Jelenko 1978**

Methods	RCT, method of allocation concealment unclear Blinding not mentioned No loss to follow-up	
Participants	19 people with burns covering more than 20% of body surface	
Interventions	<ol style="list-style-type: none"> <li>12.5% Albumin in hypertonic saline (240 mEq/L sodium, 120 mEq/L chloride, 120 mEq/L lactate) (n = 7)</li> <li>Hypertonic saline (240 mEq/L sodium, 120 mEq/L chloride, 120 mEq/L lactate) (n = 5)</li> <li>Ringer's lactate (n = 7)</li> </ol> Allocated fluid was used, guided by haemodynamic variables, to the end of resuscitation	
Outcomes	Deaths reported Haemodynamic variables	
Notes	Follow-up to end of resuscitation	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Karanko 1987**

Methods	RCT, description of allocation procedure unclear Blinding not mentioned No loss to follow-up	
Participants	32 adult men scheduled for coronary artery bypass surgery Exclusion criteria: LVEF < 40%, abnormal lung function	
Interventions	<ol style="list-style-type: none"> <li>6% Dextran 70 (n = 14)</li> <li>Ringer's lactate (n = 18)</li> </ol> Allocated fluid was used to the end of resuscitation	
Outcomes	Deaths reported Haemodynamic variables Pulmonary oedema	
Notes	Follow-up 2 weeks	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>

**Karanko 1987** (Continued)

Allocation concealment (selection bias)	Unclear risk	Unclear
---	--------------	---------

**Lang 2001**

Methods	RCT, using a closed-envelope system
Participants	42 patients scheduled for elective major abdominal surgery
Interventions	1. Ringer's lactate (n = 21) 2. 6% HES, molecular weight 139 kDa, degree of substitution 0.4 (n = 21)
Outcomes	Deaths Haemodynamics and laboratory data Tissue oxygenation Volume input and output
Notes	Follow-up period unclear

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	Adequate

**Lang 2003**

Methods	RCT, allocation concealment not clearly reported ("closed envelope system") Blinding method not reported ("...treatment in the ICU was performed by physicians who were blinded to the study")
Participants	36 patients undergoing elective major abdominal surgery Exclusion criteria: myocardial failure, renal insufficiency, severe pulmonary disease, liver dysfunction, diabetes mellitus, steroid therapy, pre-existing viral or bacterial infection and known allergic reactions to starch preparations
Interventions	1. 6% HES (n = 18) 2. Ringer's lactate (n = 18) Additional crystalloid solutions were supplied to equalise insensible fluid loss or as a solvent for drugs in group 1
Outcomes	Pro- and anti-inflammatory cytokines All patients survived
Notes	Length of follow-up not reported but all outcomes were in-hospital measures

**Risk of bias**

Lang 2003 (Continued)

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Unclear

Lee 2011

Methods	RCT method of allocation concealment not reported open label trial but the endpoints were assessed blindly
Participants	106 patients undergoing off-pump coronary artery bypass surgery and receiving with dual antiplatelet therapy (DAPT) within 5 days of surgery Exclusion criteria: emergency surgery, myocardial infarction (MI), history of previous cardiac surgery, history of bleeding diathesis or hepatic dysfunction, left ventricular ejection fraction <40%, hemoglobin <12 g/dl, platelet count <100,000 mm <sup>3</sup> , abnormal prothrombin time (international normalization ratio [INR]) and activated partial thromboplastin time (aPTT), creatinine >1.4 mg/dl, and use of glycoprotein IIb/IIIa inhibitors
Interventions	1. HES 130/0.4 (n=53) 2. Crystalloids (n=53)
Outcomes	Blood loss, infused fluid volume, urine output, and transfusion requirements, stroke, renal dysfunction, cardiac surgery reoperation, prolonged ventilation, wound infection
Notes	Death not reported

*Risk of bias*

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Not reported

Ley 1990

Methods	RCT, method of allocation concealment unclear Assessment of chest x-ray blinded No loss to follow-up
Participants	21 people undergoing coronary artery bypass grafting or valve surgery
Interventions	1. 6% Hetastarch up to 1.5 L then 5% plasma protein fraction (n = 11) 2. 0.9% Saline (n = 10) Allocated fluid was used for postoperative fluid resuscitation
Outcomes	Deaths were not reported Pulmonary and peripheral oedema Haemodynamic variables

**Ley 1990** (Continued)

Notes	Follow-up to discharge	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Lowe 1977**

Methods	RCT, allocation by sealed envelopes Blinding not mentioned No loss to follow-up	
Participants	Participants with serious trauma	
Interventions	1. 25% Albumin in Ringer's lactate (n = 77) 2. Ringer's lactate (n = 94) Allocated fluid was used throughout the pre- and intraoperative period	
Outcomes	Deaths reported	
Notes	Follow-up to 5 days postoperatively. Data on the 30 participants with chest injuries who were left out of the <a href="#">Lowe 1977</a> report, but included in Moss 1981, have been included in the meta-analysis	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Lu 2012**

Methods	Randomised controlled study	
Participants	42 patients with septic shock	
Interventions	1. Ringer's lactate (n = 20) 2. HES 130/0.4 (n = 22)	
Outcomes	Mortality, fluid replacement, use of vasoactive drugs and inflammatory markers	
Notes	-	
<b>Risk of bias</b>		

Lu 2012 (Continued)

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Unclear

Lucas 1978

Methods	RCT, randomisation was based on the last digit of each patient's case number
Participants	52 seriously injured patients
Interventions	<ol style="list-style-type: none"> <li>1. Standard resuscitation regimen ('balanced electrolyte', blood, fresh frozen plasma) plus salt-poor albumin, maximum 150 g during surgery and 150 g/day for the next 5 days (n = 27)</li> <li>2. Standard resuscitation regimen as above (n = 25)</li> </ol>
Outcomes	Deaths reported in some patients
Notes	In the final report of 94 randomised patients deaths were not reported. However, in this preliminary report of 52 injured patients deaths were reported

*Risk of bias*

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	High risk	Inadequate

Maitland 2005

Methods	RCT, open label, random allocation was assigned by the use of sealed cards No loss to follow-up
Participants	159 children with severe malaria and metabolic acidosis Exclusion criteria: pulmonary oedema, oedematous malnutrition or papilloedema
Interventions	Severe acidosis <ol style="list-style-type: none"> <li>1. 4.5% Albumin (n = 23)</li> <li>2. 0.9% Saline (n = 26)</li> </ol> Moderate acidosis <ol style="list-style-type: none"> <li>1. 4.5% Albumin (n = 33)</li> <li>2. 0.9% Saline (n = 35)</li> <li>3. Control (n = 33)</li> </ol>
Outcomes	Reduction in base deficit Neurological sequelae Death reported

**Maitland 2005** (Continued)

Notes	Length of follow-up not reported but all outcomes were in-hospital measures	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Maitland 2011**

Methods	2 stratum multicentre open, RCT	
Participants	Children aged between 60 days and 12 years, with severe febrile illness, randomly assigned within 2 strata (stratum A was children with severe febrile illness and impaired perfusion but without severe hypotension; stratum B was children with severe hypotension)	
Interventions	Children were randomly allocated to rapid volume replacement over the course of 1 hour with either: 1. 20 mL 5% Human albumin solution per kg body weight (n = 1063) 2. 20 mL 0.9% Saline solution per kg body weight (n = 1063)	
Outcomes	Mortality at 4 weeks after randomisation	
Notes	Children (n = 1044) assigned to no treatment were not included in the analysis	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	Trial numbers kept inside opaque, sealed envelopes. Opened in numerical order by clinician

**Mattox 1991**

Methods	Randomised, allocation by alternation Double-blind 2 patients excluded from the analysis as code of fluid lost	
Participants	Participants were pre-hospital trauma victims attended to by emergency personnel within 1 hour of injury, with SBP $\leq$ 90 mmHg, $\geq$ 16 years. 72% of participants had sustained penetrating trauma	
Interventions	1. 250 mL Dextran 70 in 7.5% saline (n = 211) 2. 250 mL Ringer's lactate, saline or plasmalyte (n = 211) Allocated fluid was for initial pre-hospital resuscitation only	

**Mattox 1991** (Continued)

Outcomes	Deaths reported	
Notes	Follow-up to hospital discharge or transfer	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	High risk	Inadequate

**Mazher 1998**

Methods	Patients "randomized" Blinding of carers by use of pharmacy-prepared solutions No loss to follow-up	
Participants	Patients undergoing elective coronary artery surgery Exclusion criteria: age > 75 years, ejection fraction < 35%, creatinine > 135 $\mu\text{mol/L}$ , ACE inhibitors	
Interventions	1. 5 mL/kg Polygeline (n = 10) 2. 5 mL/kg 7.2% Saline (n = 10) Allocated fluid given postoperatively over 1 hour. All patients subsequently receive polygeline and RBCs	
Outcomes	Haemodynamic variables Death	
Notes	Follow-up to discharge from ICU	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**McIntyre 2008**

Methods	A feasibility RCT	
Participants	Patients with early septic shock defined with at least 2 systemic inflammatory response syndrome criteria, infectious source and persistent hypotension after > 1 L of crystalloid fluid	
Interventions	1. Normal saline (n = 19) 2. Pentastarch (n = 21)	

**McIntyre 2008** (Continued)

Outcomes	Primary outcomes were feasibility measures for the pilot RCT. ICU and 28-day mortality were also reported	
Notes	-	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	Only the designated research pharmacist at each institution was aware of the treatment allocation for individual patients. Study fluids were prepared and blinded ahead of time by the site research pharmacist

**McNulty 1993**

Methods	RCT, method of allocation concealment not described Blinding not mentioned No loss to follow-up	
Participants	Patients following elective cardiopulmonary bypass	
Interventions	1. 5% Albumin and cell-saved blood (n = 14) 2. Plasmalyte and cell-saved blood (n = 14) Allocated fluid used as part of fluid volume replacement	
Outcomes	Deaths not reported Study was designed to look at the effect of protein infusion on the accuracy of a haematocrit measuring device	
Notes	Length of follow-up unspecified	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Metildi 1984**

Methods	RCT Blinding not mentioned No loss to follow-up	
Participants	Participants were admissions to an ICU and a trauma unit with ARDS and established pulmonary failure. Included both trauma and non-trauma patients	

**Metildi 1984** (Continued)

Interventions	1. 5% Salt-poor albumin (n = 20) 2. Ringer's lactate (n = 26) Allocated fluid was used throughout resuscitation, and if an operation was required the allocated fluid was used for volume replacement before and during the operation	
Outcomes	Deaths reported Haemodynamic variables	
Notes	Follow-up to discharge	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Modig 1983**

Methods	RCT, allocation by admission date Blinding not mentioned No loss to follow-up	
Participants	Participants were trauma admissions to an emergency department with SBP < 70 mmHg. Age range 20 to 58 years	
Interventions	1. Dextran 70 in Ringer's lactate (n = 12) 2. Ringer's lactate (n = 11) Allocated fluids were given as the initial resuscitation fluid on admission to the emergency department, and continued as needed until after the 6th day when major reconstructive surgery was undertaken	
Outcomes	Deaths reported Development of ARDS	
Notes	Follow-up to definitive reconstructive surgery	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	High risk	Inadequate

**Moretti 2003**

Methods	RCT, allocation concealment method not clearly reported (“Patients randomized...by using a closed-envelope technique”) Blinding method not clearly reported (“Researchers were unaware of the patient’s randomization”) No loss to follow-up	
Participants	90 adult patients undergoing major elective general, gynaecological, orthopaedic or urological surgery with an anticipated blood loss > 500 mL Exclusion criteria: age < 16 years, coagulopathy, renal or hepatic dysfunction and congestive heart failure	
Interventions	<ol style="list-style-type: none"> <li>1. Hetastarch-normal saline (n = 30)</li> <li>2. Hetastarch-balanced salt (n = 30)</li> <li>3. Ringer’s lactate (n = 30)</li> </ol>	
Outcomes	Postoperative nausea and vomiting Death not reported	
Notes	Follow-up to discharge	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors’ judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Myburgh 2012**

Methods	RCT, randomly assigned over an encrypted Web-based randomization system Less than 5% loss to follow-up	
Participants	7000 patients 18 years or older admitted in ICU whom the treating clinician judged to require fluid resuscitation Exclusion criteria: Patients who had received more than 1000 ml of HES before screening, those with impending or current dialysis-dependent renal failure, and those with evidence of intracranial hemorrhage Setting: New Zealand and Australia	
Interventions	<ol style="list-style-type: none"> <li>1. 6% HES 130/0.4 in 0.9% sodium chloride (n=3,500)</li> <li>2. 0.9% sodium chloride (n=3,500)</li> </ol>	
Outcomes	All-cause mortality at 90 days, kidney injury, organ failure, duration of mechanical ventilation and renal replacement therapy, cause-specific mortality	
Notes		
<b><i>Risk of bias</i></b>		

**Myburgh 2012** (Continued)

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	web-based allocation and identical packaging

**Nagy 1993**

Methods	RCT, contact with author showed it was an open-label study Blinding not mentioned No loss to follow-up
Participants	Participants were adult admissions to a trauma unit, with measurable SBP < 90 mmHg
Interventions	1. Pentastarch in 0.9% saline (n = 21) 2. Ringer's lactate (n = 20) Allocated fluid was used throughout resuscitation with the exception that colloid patients received a maximum 4 L of pentastarch, after which Ringer's lactate was given
Outcomes	Deaths were not reported Haemodynamic variables
Notes	Follow-up to discharge

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	High risk	Inadequate

**Ngo 2001**

Methods	RCT, opaque envelopes containing only treatment pack number
Participants	230 children with dengue shock syndrome
Interventions	1. Dextran 70 (n = 55) 2. 3% Gelatin (n = 56) 3. Ringer's lactate (n = 55) 4. 'Normal' saline (n = 56)
Outcomes	Initial pulse recovery time Occurrence of timing and subsequent episodes of shock Decrease in haematocrit Volume of fluid administered until recovery Complications No deaths in any group

**Ngo 2001** (Continued)

Notes	Follow-up period unclear	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	Adequate

**Nielsen 1985**

Methods	RCT, method of allocation concealment not described Blinding not mentioned No loss to follow-up	
Participants	26 patients admitted for reconstructive surgery of the abdominal aorta	
Interventions	<ol style="list-style-type: none"> <li>1. Whole blood, crystalloid plus 80 g albumin on the day of the operation, and 20 g/day for the next 3 days. Albumin given as 100 mL 20% human albumin solution (n = 13)</li> <li>2. Whole blood and crystalloid, type not specified (n = 13)</li> </ol>	
Outcomes	Deaths not reported Author when contacted confirmed that there were no deaths in either group	
Notes	Length of follow-up 4 days	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Perner 2012**

Methods	RCT Computer-generated allocation sequence and centralized, blinded allocation	
Participants	<p>804 patients 18 years of age or older who needed fluid resuscitation in the ICU, and who fulfilled the criteria for severe sepsis within the previous 24 hours</p> <p>Exclusion criteria: renal replacement therapy, kidney or liver transplant, burn injury (&gt;10%), intracranial bleeding, K &gt; 6mmol per litre, received &gt;1000 ml colloid, included in another ICU trial, withdrew from active therapy</p> <p>Setting: Denmark, Norway, Finland and Iceland</p>	
Interventions	<ol style="list-style-type: none"> <li>1. 6% HES 130/0.42 (n=400)</li> <li>2. Ringer acetate (n=400)</li> </ol>	

**Perner 2012** (Continued)

Outcomes	Death at 28 days 90 days and at time of latest follow-up , dependence on dialysis 90 days after randomization, severe bleeding, severe allergic reaction, SOFA score, acidosis, days alive without renal replacement, days alive without mechanical ventilation, days alive out of the hospital in the 90 days after randomisation	
Notes	Four patients were excluded after randomisation and two patients had incomplete outcome data in the 6% HES 130/0.42 group	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	centralised blinded allocation

**Pockaj 1994**

Methods	RCT, allocation concealment unclear Blinding not mentioned Loss to follow-up: 18/54 in colloid group, 13/53 in saline group	
Participants	Participants required fluid resuscitation as a result of vascular leak syndrome associated with interleukin-2 therapy for metastatic cancer	
Interventions	<ol style="list-style-type: none"> <li>1. 250 mL Bolus of 5% albumin in saline (n = 36 reported)</li> <li>2. 250 mL Bolus of 0.9% normal saline (n = 40 reported)</li> </ol> Boluses guided by haemodynamic variables. Both groups also received 0.45% saline with 10 mmol/L KCl	
Outcomes	Deaths Toxic effects of chemotherapy Haemodynamic variables	
Notes	-	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Prien 1990**

Methods	RCT Blinding not mentioned No loss to follow-up	
Participants	Participants were undergoing modified Whipple's operation	
Interventions	<ol style="list-style-type: none"> <li>1. 10% HES in 0.9% saline plus plasma protein fraction if requirements &gt; 20 mL/kg (n = 6)</li> <li>2. 20% human albumin solution (n = 6)</li> <li>3. Ringer's lactate (n = 6)</li> </ol> Allocated fluid was administered intraoperatively only	
Outcomes	Deaths Intestinal oedema formation	
Notes	Follow-up period was unspecified	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Rackow 1983**

Methods	RCT, allocation concealment unclear Blinding not mentioned No loss to follow-up	
Participants	Participants were aged 54 to 97 years, and had any 1 of the following pre-determined indicators of shock: SBP ≤ 90 mmHg, cardiac index < 2.2 L/minute/m <sup>2</sup> , serum arterial lactate > 18 mg/dL and WP < 15 mmHg	
Interventions	<ol style="list-style-type: none"> <li>1. 6% HES (n = 9)</li> <li>2. 5% Albumin (n = 9)</li> <li>3. 0.9% Saline (n = 8)</li> </ol> Allocated fluid was given as needed until the end of resuscitation	
Outcomes	Deaths reported Fluid balance	
Notes	Follow-up to discharge from hospital	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Rocha e Silva 1994**

Methods	RCT	
Participants	Participants were admissions to the emergency department, with SBP $\leq$ 90 mmHg and $\geq$ 16 years of age	
Interventions	<ol style="list-style-type: none"> <li>1. 6% Dextran 70 in 7.5% saline</li> <li>2. Ringer's lactate</li> </ol> Allocated fluid was used for the first IV infusion only	
Outcomes	Death was the main outcome measure, but the data are unpublished	
Notes	Follow-up to 30 days. By April 1994, 125 patients had been entered into the study	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**SAFE 2004**

Methods	RCT. Randomisation by minimisation algorithm accessed through secure website	
Participants	Patients aged $\geq$ 18 years admitted to closed multidisciplinary ICUs in 16 tertiary hospitals in Australia over 19-month period	
Interventions	<ol style="list-style-type: none"> <li>1. 4% Albumin (Albumex, CSL) (n = 3499)</li> <li>2. Normal saline (n = 3501)</li> </ol>	
Outcomes	Death Patients with new single- or multiple-organ failure Mean number of days: in ICU, in hospital, on mechanical ventilation, on renal replacement therapy	
Notes	Follow-up to 28 days	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	Adequate

**Shah 1977**

Methods	RCT, allocation by sealed envelope Blinding not mentioned No loss to follow-up
Participants	Patients with severe, multiple trauma and SBP < 90 mmHg. All patients were adults and both sexes were included
Interventions	1. 5% Salt-poor albumin in Ringer's lactate (n = 9) 2. Ringer's lactate (n = 11) Volume infused guided by physiological parameters
Outcomes	Death reported Haemodynamic variables
Notes	Length of follow-up not stated

***Risk of bias***

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Shires 1983**

Methods	Patients 'assigned randomly' Blinding not mentioned No loss to follow-up
Participants	People undergoing aortic reconstruction surgery No exclusion criteria mentioned
Interventions	1. Plasmanate (n = 9) 2. Ringer's lactate (n = 9) Allocated fluid used guided by haemodynamic variables until the first postoperative morning. All patients then received 0.45% saline
Outcomes	Pulmonary oedema Haemodynamic variables Death
Notes	Follow-up to 2 days postoperative

***Risk of bias***

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Sirieux 1999**

Methods	Patients “randomly assigned” Blinding not described 2 patients excluded after randomisation due to arrhythmias on giving the fluid (both in hypertonic saline group)
Participants	Patients undergoing mitral valve repair Exclusion criteria: LVEF < 0.4, systolic PAP > 50 mmHg, coagulation disorders, creatinine > 150 mmol/L, electrolyte imbalance, diabetes, previous atrial fibrillation lasting > 1 year
Interventions	1. 250 mL 7.2% Hypertonic saline, 6% HES (n = 8) 2. 250 mL 7.2% Hypertonic saline (n = 10) 3. 250 mL 6% HES (n = 8) Fluid given over 15 minutes, 1 hour after admission to postoperative ICU
Outcomes	Haemodynamic variables Deaths reported Side effects (severe hypotension: 1 patient in group 1 and 2 patients in group 2; arrhythmias: 1 patient in group 1, 3 patients in group 2 and 1 patient in group 3)
Notes	Follow-up to discharge from hospital (all within 10 days)

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Unclear

**Skillman 1975**

Methods	RCT, allocation concealment unclear Blinding not mentioned No loss to follow-up
Participants	Participants were undergoing elective abdominal reconstructive surgery
Interventions	1. 25% Salt-poor albumin 1 g/kg and 5% albumin 1 L (n = 7) 2. Ringer's lactate Allocated fluid was given intraoperatively. All patients received crystalloids only for pre-loading before surgery
Outcomes	Deaths were not reported
Notes	-

***Risk of bias***

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

**Skillman 1975** (Continued)

Allocation concealment (selection bias)	Unclear risk	Unclear
---	--------------	---------

**Tollofsrud 1995**

Methods	RCT, allocation by sealed envelopes Blinding not mentioned No loss to follow-up
Participants	Participants were adults in need of volume replacement during and after coronary artery bypass surgery
Interventions	1. Haemaccel (n = 10) 2. Dextran 70 (n = 10) 3. Albumin 40 (n = 10) 4. Ringer's lactate (n = 10) Allocated fluid was used throughout resuscitation
Outcomes	Deaths reported Fluid balance
Notes	Follow-up to 48 hours

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Unclear

**Tollofsrud 1998**

Methods	RCT, allocation by sealed envelope Described as double blind No loss to follow-up mentioned
Participants	Patients with 3 vessel coronary artery disease undergoing elective coronary artery surgery Exclusion criteria: LVEF < 0.4, ventricular aneurysm, significant arrhythmia, diabetes, renal failure, lung disease
Interventions	1. 4 mL/kg of 75 mg/mL hypertonic saline in dextran 70 60 mg/mL over 30 minutes (n = 10) 2. Same volume and rate of isotonic saline (n = 10) Fluid given just after surgery while still in operating theatre. Ringer's lactate for additional fluid
Outcomes	Fluid balance Haemodynamic variables Deaths not reported

**Tollofsrud 1998** (Continued)

Notes	Follow-up to 48 hours	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Upadhyay 2004**

Methods	Open-label randomised trial, allocation by sealed envelope No loss to follow-up mentioned	
Participants	60 patients with septic shock aged 1 month to 12 years Exclusion criteria: age < 1 month, multiorgan failure and immunodeficiency states	
Interventions	<ol style="list-style-type: none"> <li>1. Normal saline (n = 31)</li> <li>2. Polymer from degraded gelatin in saline (n = 29)</li> </ol>	
Outcomes	Haemodynamic data Death reported	
Notes	Length of follow-up not reported but all outcomes were in-hospital measures	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Vassar 1990**

Methods	RCT, allocation concealment unclear Double-blind study (solutions prepared in identical containers) No loss to follow-up	
Participants	Participants were emergency department admissions with trauma and SBP < 80 mmHg and ≥ 18 years of age Exclusion criteria: pregnant women and people with pre-existing cardiac, hepatic or renal disease	
Interventions	<ol style="list-style-type: none"> <li>1. 6% Dextran 70 in 7.5% saline (n = 23)</li> <li>2. Ringer's lactate (n = 24)</li> </ol> Allocated fluids were given as the initial resuscitation in the emergency department. Additional isotonic crystalloids (Ringer's lactate) were given as needed	

**Vassar 1990** (Continued)

Outcomes	Deaths reported Haemodynamic variables	
Notes	Follow-up to hospital discharge	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Vassar 1991**

Methods	RCT, allocation by randomised sequence of coded containers Double-blind study No loss to follow-up	
Participants	Participants were pre-hospital trauma cases undergoing helicopter transport to an emergency centre, with SBP $\leq$ 100 mmHg and $\geq$ 18 years Exclusion criteria: pre-existing cardiac renal, hepatic or neurological disease; peripheral oedema	
Interventions	<ol style="list-style-type: none"> <li>1. 4.2% Dextran 70 in 7.5% saline or 6% dextran 70 in 7.5% saline (n = 83)</li> <li>2. Ringer's lactate (n = 83)</li> </ol> Fluids were given as the initial resuscitation fluid in the pre-hospital setting. Supplemental isotonic fluids were given at the discretion of the flight nurses	
Outcomes	Deaths reported Haemodynamic variables	
Notes	Follow-up to discharge. Allocation was to 4.2% dextran 70, to 6% dextran 70, or to crystalloid; for the calculation of the summary effect measure, the 2 dextran groups were combined	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	Adequate

**Vassar 1993a**

Methods	RCT, allocation concealed by random sequence of identical containers Double-blind study 36 people excluded post randomisation as deemed not to have met eligibility criteria No loss to follow-up
Participants	Participants, who were undergoing ambulance transport to an emergency centre, SBP $\leq$ 90 mmHg, $\geq$ 18 years Exclusion criteria: asystolic; undergoing CPR; lack sinus complex on ECG; > 2 hours after trauma; pregnant; pre-existing seizures; bleeding disorder; hepatic, cardiac or renal disease
Interventions	1. 6% Dextran 70 in 7.5% saline (n = 89) 2. 7.5% Saline (n = 85) 3. 0.9% Saline (n = 84) Participants received 250 mL of the allocated fluid in the pre-hospital setting. Additional isotonic crystalloids were given as needed
Outcomes	Deaths reported Haemodynamic variables Trauma scores
Notes	Follow-up was to discharge from hospital

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	Adequate

**Vassar 1993b**

Methods	RCT, allocation concealed by sequential use of coded identical containers Double-blind study 39/233 patients excluded as deemed not to meet eligibility criteria, unclear from which groups
Participants	Participants were pre-hospital trauma cases undergoing helicopter transport to an emergency centre, SBP $\leq$ 100 mmHg, $\geq$ 18 years Exclusion criteria: asystolic; undergoing CPR; lack sinus complex on ECG; > 2 hours after trauma; pregnant; pre-existing seizures; bleeding disorder; hepatic, cardiac or renal disease
Interventions	1. 12% Dextran 70 in 7.5% saline (n = 49) 2. 6% Dextran 70 in 7.5% saline (n = 50) 3. 7.5% Saline (n = 50) 4. Ringer's lactate (n = 45) Participants received 250 mL of the allocated fluid in the pre-hospital setting. Additional isotonic crystalloids were given as needed

Vassar 1993b (Continued)

Outcomes	Deaths reported Haemodynamic variables Trauma scores and neurological outcome scores	
Notes	Follow-up to hospital discharge	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	Adequate

Verheij 2006

Methods	RCT, allocation concealment by "the sealed envelope method" Blinding method not reported No loss to follow-up	
Participants	67 patients with presumed hypovolaemia after cardiac and major vascular surgery Exclusion criteria: age > 79 years and known anaphylactoid reaction to colloids	
Interventions	<ol style="list-style-type: none"> <li>1. Saline (n = 16)</li> <li>2. Gelatin (n = 16)</li> <li>3. HES (n = 16)</li> <li>4. Albumin (n = 16)</li> </ol>	
Outcomes	Haemodynamic data Death not reported	
Notes	Length of follow-up not reported but all outcomes were in-hospital measures	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

Virgilio 1979

Methods	Allocation "by random number" Blinding not mentioned No loss to follow-up	
Participants	Participants were undergoing abdominal aortic surgery	

**Virgilio 1979** (Continued)

Interventions	1. 5% Albumin (n = 15) 2. Ringer's lactate (n = 14) Allocated fluid was used during operation for maintenance of pre-defined physiological parameters, and the resuscitation was continued with the allocated fluid until the day following the operation. This was followed by 5% dextrose in half-normal saline, with potassium chloride as needed	
Outcomes	Deaths reported	
Notes	Follow-up 2.5 weeks	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Wahba 1996**

Methods	Patients "randomly allocated" Blinding not mentioned 2 patients excluded as they required reoperation for bleeding	
Participants	22 adults in need of volume replacement following coronary artery bypass surgery Exclusion criteria: abnormal left ventricular function, platelet active medication or heparin	
Interventions	1. Haemaccel (n = 10) 2. Ringer's lactate (n = 10) Allocated fluid was used from the time of admission to ICU following operation, to the end of resuscitation	
Outcomes	Deaths reported Pulmonary oedema	
Notes	Follow-up to discharge	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Wills 2005**

Methods	RCT, allocation concealed by specially prepared cardboard containers Method of blinding not mentioned No loss to follow-up
Participants	512 children with dengue shock syndrome aged 2 to 15 years
Interventions	Children with immoderately severe shock were randomised to the 3 interventions <ol style="list-style-type: none"> <li>1. Ringer's lactate (n = 128)</li> <li>2. 6% Dextran 70 (n = 126)</li> <li>3. 6% HES 200/0.5 (n = 129)</li> </ol> Children with severe shock were randomised only to either of the 2 colloids interventions: <ol style="list-style-type: none"> <li>1. 6% Dextran 70 (n = 67)</li> <li>2. 6% HES 200/0.5 (n = 62)</li> </ol>
Outcomes	Requirement for supplemental intervention with rescue colloid Time taken to achieve initial cardiovascular stability Time taken to achieve sustained cardiovascular stability Volume required Change in haematocrit Days in hospital 1 death reported but not specified in which group
Notes	Length of follow-up not clear

***Risk of bias***

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Low risk	Adequate

**Woittiez 1997**

Methods	RCT, allocation concealment by sealed opaque envelopes No information on blinding or loss to follow-up
Participants	60 patients who had developed hypoalbuminaemia (< 20 g/L) after major surgery 2 patients died after randomisation and before treatment started. They were excluded from the analysis
Interventions	<ol style="list-style-type: none"> <li>1. Saline (500 mL/24 hours) (n = 16)</li> <li>2. 20% Albumin (300 mL/24 hours) (n = 15)</li> <li>3. 10% HES (500 mL/24 hours) for 3 days (n = 27)</li> </ol> Aim was to restore COP
Outcomes	Changes in fluid balance, serum albumin, COP and clinical signs of oedema were followed daily Death rates supplied by the author

Woittiez 1997 (Continued)

Notes	Length of follow-up unspecified	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

Wu 2001

Methods	RCT. No details given of randomisation method	
Participants	41 adolescent or adult patients in emergency department suffering from shock	
Interventions	<ol style="list-style-type: none"> <li>1. 4% Modified fluid gelatin: succinated gelatin 40 g/L, sodium chloride 7 g/L, sodium hydroxide 1.36 g/L (n = 18)</li> <li>2. Ringer's lactate (n = 16)</li> </ol>	
Outcomes	Death Haemodynamic variables	
Notes	Not intention-to-treat: 5 patients who received blood transfusion and 2 who had surgery within the first hour of resuscitation were dropped from the analysis Length of follow-up not clear	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

Younes 1992

Methods	Randomised "in a double blind fashion" Blinding by use of similar bottles No loss to follow-up	
Participants	Participants were emergency department admissions, SBP < 80 mmHg, ≥ 19 years Exclusion criteria: pregnant, pre-existing cardiac or metabolic disease	
Interventions	<ol style="list-style-type: none"> <li>1. 6% Dextran 70 in 7.5% saline (n = 35)</li> <li>2. 7.5% Saline (n = 35)</li> <li>3. 0.9% Saline (n = 35)</li> </ol> Allocated fluid was for initial bolus of 250 mL, followed by isotonic crystalloids as needed	

**Younes 1992** (Continued)

Outcomes	Deaths reported Fluid balance	
Notes	Follow-up to discharge from hospital	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Younes 1994**

Methods	Trial conducted in a "double blind randomised fashion" Blinding by use of coded, identical containers	
Participants	Participants were trauma admissions to the emergency department requiring treatment for haemorrhagic hypovolaemia; all were over 15 years old Exclusion criteria: pregnant, cardiac or renal failure, cardiac arrest on arrival	
Interventions	1. 6% Dextran 70 in 7.5% saline (n = 101) 2. 0.9% Saline (n = 111) Allocated fluid was for the first IV infusion only	
Outcomes	Deaths reported Complications	
Notes	Follow-up period was 30 days	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Younes 1998**

Methods	RCT, allocation by sealed envelope Blinding not mentioned No apparent loss to follow-up	
Participants	Trauma patients SBP < 90 mmHg admitted to the emergency department, with no previous treatment	
Interventions	1. 10% Pentastarch (n = 12) 2. 0.9% Saline (n = 11) Fluid given in 250 mL boluses until systolic blood pressure > 100 mmHg	

**Younes 1998** (Continued)

Outcomes	Deaths reported No complications reported in either group	
Notes	Follow-up to 24 hours	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Zetterstrom 1981a**

Methods	The patients were randomly divided into 2 groups Allocation concealment was by sealed opaque envelopes (information supplied by study author) Blinding not mentioned No loss to follow-up	
Participants	Adults undergoing elective major abdominal surgery	
Interventions	<ol style="list-style-type: none"> <li>1. Standard volume replacement regimen (1 L dextran 70 then up to 4 units of RBC with electrolyte, then whole blood or RBC with plasma; postoperative patients were given crystalloids and whole blood) plus 20% human albumin solution 100 mL at end of operation, 200 mL to 300 mL on same day, then 200 mL on first postoperative day, then 100 mL for next 3 days (n = 15)</li> <li>2. Standard volume replacement regimen (as above) (n = 15)</li> </ol>	
Outcomes	Deaths reported Haemodynamic variables	
Notes	Length of follow-up unspecified	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Zetterstrom 1981b**

Methods	Patients were randomly divided into 2 groups Allocation concealment was by sealed opaque envelopes (information supplied by study author) Blinding not mentioned No loss to follow-up	
Participants	18 patients who had undergone elective abdominal aortic surgery No exclusions mentioned	
Interventions	1. 5% Human albumin solution (n = 9) 2. Ringer's lactate solution (n = 9) Administration guided by pulmonary arterial occlusion pressure	
Outcomes	Deaths reported Haemodynamic variables	
Notes	Follow-up to discharge from hospital	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

**Zhu 2011**

Methods	RCT	
Participants	135 participants with severe sepsis	
Interventions	1. 7.5% Hypertonic saline plus 6% HES 130/0.4 (n = 45) 2. Ringer's lactate plus 6% HES 130/0.4 (n = 45) 3. Ringer's lactate (n = 45)	
Outcomes	Biomarkers, fluid requirements, and MODS. Mortality was also reported	
Notes	-	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	Unclear

ACE: angiotensin-converting enzyme; ARDS: adult respiratory distress syndrome; ASA: American Society of Anesthesiologists; bpm: beats per minute; COP: colloid osmotic pressure; CPR: cardiopulmonary resuscitation; GI: gastrointestinal; HES: hydroxyethyl starch; HR: heart rate; ICU: intensive care unit; IV: intravenous; LVEDP: left ventricular end diastolic pressure; LVEF: left ventricular

ejection fraction; MODS: multiple organ dysfunction score; PAP: pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; RBC: red blood cell; RCT: randomised controlled trial; SBP: systolic blood pressure; TBSA: total body surface area; WP: wedge pressure.

### Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Artru 1989	Intervention to control intracranial pressure not directed at fluid resuscitation
Bocanegra 1966	Study contained 2 quasi-randomised comparisons of colloid with glucose and plasma/saline with saline. In both studies, the control solution was only given IV if the patient was in coma or shock. It was therefore not a reasonable comparison of colloid and crystalloid
Boldt 1996	All groups received some colloid
Boldt 2007	Comparison was not between colloids and crystalloids, rather 2 different colloid solutions
Bothner 1998	Participants were having minor elective surgery, therefore not considered to be critically ill
Breheme 1993	Intervention directed at haemodilution, not at volume replacement
Bueno R 2004	The participants had elective surgery
Chin 2006	Participants were undergoing elective surgery, therefore not considered to be critically ill
Golub 1994	Albumin given solely as a nutritional supplement
Goslinga 1992	Intervention directed at haemodilution, not volume replacement
Green 2008	Article is a review
Greenhalgh 1995	Intervention directed at the maintenance of serum albumin levels, not for volume replacement
Hauser 1980	Cross-over trial
Ko 2007	Comparison of crystalloids and colloids as pre-loading solutions
Krashennikov 2007	Not an RCT
Lagonidis 1995	Intervention was pre-loading for coronary artery bypass surgery
Lange 2011	Article was a review
Lobo 2008	Experiment conducted on rabbits
Marhofer 1999	Trial of fluid for pre-loading before spinal anaesthesia

(Continued)

Mittermayr 2007	Patients were undergoing elective surgery
Mittermayr 2008	Outcome was the change in concentration of tissue-type plasminogen activator
Morrison 2011	Study evaluated the effect of hypertonic saline in patients with blunt head injury
Niemi 2008	Solutions were used for pump priming
Nilsson 1980	Albumin given as a nutritional supplement
Oliviera 2002	The participants had sepsis
Paton-Gay 2007	The outcome was non-relevant to comparing crystalloids and colloids
Paul 2003	The participants had elective surgery
Rehm 2001	2 colloids (albumin and hetastarch) compared
Steinberg 1989	Cross-over trial
Tiryakioglu 2008	Patients were undergoing elective surgery and not considered critically ill. Also, the solutions were used as priming solutions
Tseng 2008	Crystalloid and colloid treatment was not randomised
Valetova 2007	Patients were randomised depending upon their treatment not prior to treatment
van der Heijden 2009	The report did not provide separate data for the 3 arms that received colloids (gelatin 4%, hydroxyethyl starch 6% and albumin 5%)
Vercueil 2006	Article is a review
Wilkes 2001	1 group received saline plus hetastarch, the other received 'balanced' fluid plus hetastarch. Thus, each group received both a colloid and a crystalloid. This conflicts with the purpose our review, which compares patients who had 1 of these with patients who had the other
Woods 1993	This quasi-randomised trial looked at albumin supplementation in postoperative patients, with the aim of maintaining the serum albumin. Since the main aim of giving albumin was not to replace volume, the study was excluded

## Characteristics of ongoing studies *[ordered by study ID]*

### RASP trial

Trial name or title	Lactated Ringer Versus Albumin in Early Sepsis Therapy (RASP)
Methods	RCT
Participants	360 patients with severe sepsis or septic shock
Interventions	1. Ringer's lactate 2. 4% Albumin
Outcomes	28 days all-cause mortality
Starting date	May 2012
Contact information	Juliano P Almeida, Cancer Institute of Sao Paulo, School of Medicine, University of Sao Paulo
Notes	<a href="#">NCT01337934</a>

HES: hydroxyethyl starch; ICU: intensive care unit; RCT: randomised controlled trial.

## DATA AND ANALYSES

### Comparison 1. Colloid versus crystalloid (add-on colloid)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Deaths	56		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Albumin or plasma protein fraction	24	9920	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.93, 1.10]
1.2 Hydroxyethyl starch	25	9147	Risk Ratio (M-H, Fixed, 95% CI)	1.10 [1.02, 1.19]
1.3 Modified gelatin	11	506	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.49, 1.72]
1.4 Dextran	9	834	Risk Ratio (M-H, Fixed, 95% CI)	1.24 [0.94, 1.65]

### Comparison 2. Colloid and hypertonic crystalloid versus isotonic crystalloid

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Deaths	11		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Albumin or plasma protein fraction	1	14	Risk Ratio (M-H, Fixed, 95% CI)	0.5 [0.06, 4.33]
1.2 Hydroxyethyl starch	1	90	Risk Ratio (M-H, Fixed, 95% CI)	0.25 [0.03, 2.15]
1.3 Modified gelatin	0	0	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.4 Dextran	9	1879	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.79, 1.06]

### Comparison 3. Colloid versus hypertonic crystalloid


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Deaths	3		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
1.1 Albumin or plasma protein fraction	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Hydroxyethyl starch	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.3 Modified gelatin	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.4 Dextran	0		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

### Analysis 1.1. Comparison 1 Colloid versus crystalloid (add-on colloid), Outcome 1 Deaths.


Review: Colloids versus crystalloids for fluid resuscitation in critically ill patients

Comparison: 1 Colloid versus crystalloid (add-on colloid)


Outcome: 1 Deaths



(... Continued)



(Continued ...)




## Analysis 2.1. Comparison 2 Colloid and hypertonic crystalloid versus isotonic crystalloid, Outcome 1 Deaths.

Review: Colloids versus crystalloids for fluid resuscitation in critically ill patients

Comparison: 2 Colloid and hypertonic crystalloid versus isotonic crystalloid

Outcome: 1 Deaths



### Analysis 3.1. Comparison 3 Colloid versus hypertonic crystalloid, Outcome 1 Deaths.

Review: Colloids versus crystalloids for fluid resuscitation in critically ill patients

Comparison: 3 Colloid versus hypertonic crystalloid

Outcome: 1 Deaths

Study or subgroup	Colloid n/N	Crystalloid n/N	Risk Ratio	
			M-H,Fixed,95% CI	M-H,Fixed,95% CI
1 Albumin or plasma protein fraction Bowser-Wallace 1986	3/19	0/19	7.00 [ 0.39, 126.92 ]	
2 Hydroxyethyl starch Sirieix 1999	0/8	0/8	0.0 [ 0.0, 0.0 ]	
3 Modified gelatin Mazher 1998	0/10	0/10	0.0 [ 0.0, 0.0 ]	
4 Dextran				

0.01 0.1 10 100  
Favours colloid Favours crystalloid

## APPENDICES

### Appendix I. Search strategy

#### Cochrane Injuries Group Specialised Register

colloid\* or hydrocolloid\* or crystalloid\*

#### Cochrane Central Register of Controlled Trials (*The Cochrane Library*)

#1 MeSH descriptor Plasma Volume explode all trees

#2 MeSH descriptor Fluid Therapy explode all trees

#3 MeSH descriptor Resuscitation explode all trees

#4 (fluid\* OR volume OR plasma OR rehydrat\* OR blood OR oral) next (replac\* OR therapy OR substitut\* OR restor\* OR resuscitat\* OR rehydrat\*):ti,ab,kw

#5 (#1 OR #2 OR #3 or #4)

#6 MeSH descriptor Colloids explode all trees

- #7 MeSH descriptor Hetastarch explode all trees
- #8 MeSH descriptor Rehydration Solutions explode all trees
- #9 MeSH descriptor Isotonic Solutions explode all trees
- #10 MeSH descriptor Serum explode all trees
- #11 MeSH descriptor Plasma explode all trees
- #12 MeSH descriptor Plasma Substitutes explode all trees
- #13 MeSH descriptor Albumins explode all trees
- #14 MeSH descriptor Serum Albumin explode all trees
- #15 (colloid\* OR hydrocolloid\* or crystalloid\* OR albumin\* OR albumen\* OR plasma OR starch\* OR dextran\* OR gelofus\* OR hemacel\* OR haemacel\* OR serum OR hetastarch OR isotonic OR ringer\* OR gelatin\* OR gentran\* OR pentastarch\* OR pentaspan\* OR hartman OR sodium OR potassium OR saline):ti
- #16 (Isotonic next saline next solution\*) OR (Blood next substitut\*) OR (blood next expan\*) OR (plasma next volume next expan\*) OR (volume next expan\*)
- #17 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16)
- #18 (#5 AND #17)

**MEDLINE (OvidSP)**

- 1. exp Plasma Volume/
- 2. exp Fluid Therapy/
- 3. exp Resuscitation/
- 4. ((fluid\* or volume or plasma or rehydrat\* or blood or oral) adj1 (replac\* or therapy or substitut\* or restor\* or resuscitat\* or rehydrat\*)).ab,ti.
- 5. 1 or 2 or 3 or 4
- 6. exp Colloids/
- 7. exp Hetastarch/
- 8. exp Rehydration Solutions/
- 9. exp Isotonic Solutions/
- 10. exp Serum/
- 11. exp Plasma/
- 12. exp Plasma Substitutes/
- 13. exp Albumins/
- 14. exp Serum Albumin/
- 15. (colloid\* or hydrocolloid\* or crystalloid\* or albumin\* or albumen\* or plasma or starch\* or dextran\* or gelofus\* or hemacel\* or haemacel\* or serum or hetastarch or isotonic or ringer\* or gelatin\* or gentran\* or pentastarch\* or pentaspan\* or hartman or sodium or potassium or saline).ti.
- 16. ((Isotonic adj1 saline adj1 solution\*) or (Blood adj1 substitut\*) or (blood adj1 expan\*) or (plasma adj1 volume adj1 expan\*) or (volume adj1 expan\*)).ab,ti.
- 17. or/6-16
- 18. 5 and 17
- 19. randomi?ed.ab,ti.
- 20. randomized controlled trial.pt.
- 21. controlled clinical trial.pt.
- 22. placebo.ab.
- 23. clinical trials as topic.sh.
- 24. randomly.ab.
- 25. trial.ti.
- 26. 19 or 20 or 21 or 22 or 23 or 24 or 25
- 27. (animals not (humans and animals)).sh.
- 28. 26 not 27
- 29. 18 and 28

**EMBASE (OvidSP)**

- 1. exp plasma volume/

2. exp fluid therapy/
3. exp fluid resuscitation/
4. ((fluid\* or volume or plasma or rehydrat\* or blood or oral) adj1 (replac\* or therapy or substitut\* or restor\* or resuscitat\* or rehydrat\*)).ab,ti.
5. 1 or 2 or 3 or 4
6. exp colloid/
7. exp hetastarch/
8. exp "solution and solubility"/
9. exp isotonic solution/
10. exp serum/
11. exp serum albumin/
12. exp crystalloid/
13. exp hetastarch/
14. exp plasma/
15. exp plasma substitute/
16. exp albumin/
17. exp serum albumin/
18. or/6-17
19. (th or ad or iv).fs.
20. 18 and 19
21. (colloid\* or hydrocolloid\* or crystalloid\* or albumin\* or albumen\* or plasma or starch\* or dextran\* or gelofus\* or hemacel\* or haemacel\* or serum or hetastarch or isotonic or ringer\* or gelatin\* or gentran\* or pentastarch\* or pentaspan\* or hartman or sodium or potassium or saline).ti.
22. ((Isotonic adj1 saline adj1 solution\*) or (Blood adj1 substitut\*) or (blood adj1 expan\*) or (plasma adj1 volume adj1 expan\*) or (volume adj1 expan\*)).ab,ti.
23. 20 or 21 or 22
24. exp Randomized Controlled Trial/
25. exp controlled clinical trial/
26. randomi?ed.ab,ti.
27. placebo.ab.
28. \*Clinical Trial/
29. randomly.ab.
30. trial.ti.
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. exp animal/ not (exp human/ and exp animal/)
33. 31 not 32
34. 5 and 23 and 33

**ISI Web of Science: Science Citation Index Expanded, ISI Web of Science: Conference Proceedings Citation Index-Science**

- #1 colloid\* OR hydrocolloid\* or crystalloid\*)
- #2 (Isotonic NEAR/1 saline NEAR/1 solution\*) OR (Blood NEAR/1 substitut\*) OR (blood NEAR/1 expan\*) OR (plasma NEAR/1 volume NEAR/1 expan\*) OR (volume NEAR/1 expan\*))
- #3 #1 OR #2
- #4 (fluid\* OR volume OR plasma OR rehydrat\* OR blood OR oral) NEAR/2 (replac\* OR therapy OR substitut\* OR restor\* OR resuscitat\* OR rehydrat\*)
- #5 (random\*) NEAR/3 (study or trial)
- #6 (singl\* OR doubl\* OR trebl\* OR tripl\*) NEAR/3 (blind\* OR mask\*) NEAR/3 (study or trial)

**PubMed**

(((((colloid\* OR hydrocolloid\* OR crystalloid\* OR albumin\* OR albumen\* OR plasma OR starch\* OR dextran\* OR gelofus\* OR hemacel\* OR haemacel\* OR serum OR hetastarch OR isotonic OR ringer\* OR gelatin\* OR gentran\* OR pentastarch\* OR pentaspan\* OR hartman OR sodium OR potassium OR saline) AND title)) OR (colloids[MeSH Terms])) AND (((fluid\* OR volume OR plasma OR rehydrat\* OR blood OR oral) AND (replac\* OR therapy OR substitut\* OR restor\* OR resuscitat\* OR rehydrat\*))

OR (((plasma volume[MeSH Terms]) OR fluid therapy) OR resuscitation)))) AND ((randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly allocated OR at random OR randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized controlled trials[mh]) NOT ((models, animal[mh] OR Animals[mh] OR Animal Experimentation[mh] OR Disease Models, Animal[mh] OR Animals, Laboratory[mh]) NOT (Humans[mh])))

## WHAT'S NEW

Last assessed as up-to-date: 17 October 2012.

Date	Event	Description
31 January 2013	New citation required and conclusions have changed	New study data have been included. The conclusions of the review have changed
17 January 2013	New search has been performed	Four new studies have been included ( <a href="#">Guidet 2012</a> , <a href="#">Lee 2011</a> , <a href="#">Myburgh 2012</a> , and <a href="#">Perner 2012</a> ). Mortality data from a reply letter ( <a href="http://bj.oxford-journals.org/content/107/5/693/reply">http://bj.oxford-journals.org/content/107/5/693/reply</a> ) of a previous included study was added ( <a href="#">James 2011</a> ).

## HISTORY

Protocol first published: Issue 4, 1997

Review first published: Issue 4, 1997

Date	Event	Description
17 October 2012	Amended	Copy edits made to graph labels.
8 June 2012	Amended	Copy edits made and citation corrected.
14 May 2012	New citation required but conclusions have not changed	An updated search was conducted in March 2012. Nine new trials have been included ( <a href="#">Bulger 2011</a> ; <a href="#">Cooper 2006</a> ; <a href="#">Du 2011</a> ; <a href="#">Dubin 2010</a> ; <a href="#">James 2011</a> ; <a href="#">Lu 2012</a> ; <a href="#">Maitland 2011</a> ; <a href="#">McIntyre 2008</a> ; <a href="#">Zhu 2011</a> ) The analysis and results sections have been revised accordingly. The conclusions remain unchanged. 3 ongoing studies were identified (CHEST Trial; <a href="#">RASP trial</a> ; The 6S trial). We plan to update this review once the CHEST Trial (a large phase 3 trial comparing 6% hydroxyethyl starch and saline) is published
16 March 2012	New search has been performed	An updated search was conducted in March 2012.

(Continued)

10 February 2011	New citation required but conclusions have not changed	The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (Boldt 2009). As the editors who revealed this fabrication point out (Reinhart 2011; Shafer 2011), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author (Boldt 1986, Boldt 1993, Boldt 2001, Lang 2001, Lang 2003) on the conclusions of the review. The authors of the review have changed.
17 April 2009	New search has been performed	April 2009 An updated search for new trials was conducted in October 2008. One new study was included (Brunkhorst 2008). The analysis, results and discussion sections have been revised accordingly
16 July 2008	Amended	Converted to new review format.
1 July 2007	New search has been performed	August 2007 An updated search for new trials was conducted in December 2006. Ten new studies were included (Evans 2003, Cifra 2003, Fries 2004, Guo 2003, Lang 2003, Maitland 2005, Moretti 2003, Upadhyay 2004, Verheij 2006, Wills 2005). The analysis, results and discussion sections have been revised accordingly

## CONTRIBUTIONS OF AUTHORS

July 2007: PP and IR examined trials for inclusion or exclusion, reaching agreement by discussion. PP and IR extracted data from the new studies. PP, IR and KK amended the text of the review.

April 2009: IR and MP examined trials for inclusion or exclusion, reaching agreement by discussion. IR and MP extracted data from the new study. MP amended the text of the review. PP edited the final version.

February 2011: The Cochrane Injuries Group amended the text (Emma Sydenham, Managing Editor). Both authors agreed with the changes to the manuscript.

November 2012: PP and IR examined trials for inclusion or exclusion, reaching agreement by discussion. PP and KK extracted data from the new studies. PP amended the text of the review. All the authors agreed with the changes in the manuscript.

## DECLARATIONS OF INTEREST

None known.

## SOURCES OF SUPPORT

### Internal sources

- Institute of Child Health, University of London, UK.
- UK Cochrane Centre, NHS R&D Programme, UK.

### External sources

- NHS R&D Programme: Mother and Child Health, UK.
- Cochrane Review Incentive Scheme, Department of Health, UK.

## NOTES

The editorial group is aware that a clinical trial by Professor Joachim Boldt has been found to have been fabricated ([Boldt 2009](#)). As the editors who revealed this fabrication point out ([Reinhart 2011](#); [Shafer 2011](#)), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews that include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author ([Boldt 1986](#); [Boldt 1993](#); [Boldt 2001](#); [Lang 2001](#); [Lang 2003](#)) on the conclusions of the review.

Emma Sydenham, Managing Editor, performed the sensitivity analysis.

## INDEX TERMS

### Medical Subject Headings (MeSH)

Albumins [therapeutic use]; Blood Proteins [therapeutic use]; Colloids [\*therapeutic use]; Critical Illness [mortality; \*therapy]; Dextrans [therapeutic use]; Fluid Therapy [methods]; Gelatin [therapeutic use]; Hetastarch [therapeutic use]; Isotonic Solutions [\*therapeutic use]; Plasma Substitutes [therapeutic use]; Randomized Controlled Trials as Topic; Rehydration Solutions [therapeutic use]; Resuscitation [\*methods]

### MeSH check words

Humans